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CHAPTER I 
 
INTRODUCTION 
 
1.1 Significance 
Selective targeting of damaged or diseased cells is a concept with great potential 
to revolutionize the manner in which effective therapies are administered.  Many current 
treatments are administered systematically, allowing the therapy equal access to both 
target and nontarget cells throughout the entire body.  The introduction of contrast agents 
for clinical imaging and biosensing approaches is similarly constrained by ubiquitous 
systemic delivery, resulting in high background noise and reduced sensitivity.  Targeting 
of imaging approaches and/or therapies to specific cell types, however, has the potential 
to deliver high concentrations to specific tissues, enabling sensitive detection and 
diagnostics as well as therapies that minimize collateral damage to nontarget cells.  
Several targeting strategies, including magnetic and ligand-receptor interactions, have 
been employed to achieve this goal both in vitro and in vivo (1).  Many recent studies 
have focused specifically on ligand-receptor interactions (2) or structural modification by 
enzymes (3,4) to achieve specific action.  The work presented here describes a hybrid 
approach designed to impart increased target sensitivity and to overcome the limitations 
of single-modality targeting methods. 
Nanoparticles confer multiple advantages to tissue-specific targeting not available 
with molecular structures alone.  Prominent among these is the flexibility offered by 
physical characteristics of the nanoparticle base.  As particle size strongly affects tissue 
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biodistribution, the small physical size of the NP base allows the construct to retain much 
of the interstitial mobility that is characteristic of molecular structures.  However, fine 
control over optical and chemical properties (for imaging and biosensing applications) 
and surface chemistry (for attachment of active molecules) is possible in the synthesis of 
nanoparticles, allowing the formulation of a multitude of populations with distinct 
characteristics (2,3).  The attachment of multiple bioactive molecules and the capability 
for colocalization of different targeting agents further extends the capability of the 
nanoparticle format, enabling the creation of multifunctional nanoprobes and multivalent 
target interaction.  The combination of optical properties and differing surface 
chemistries results in a modular format, enabling the development of nanoprobes that can 
be customized to suit the specific target, imaging or sensing format, or treatment 
modality. 
Beyond the physical and chemical characteristics of the construct, appropriate 
selection of the target antigen is vital to the success of any targeting approach.  As 
targeted constructs typically interact directly with surface proteins, the efficacy of tissue-
specific delivery is strongly modulated by the relative concentration of the target.  Ideal 
candidate molecules are expressed only on target cells or within the target tissue.  While 
appropriate for in vitro applications in which experimental conditions can be tightly 
controlled, this caveat is predictably demanding when applied to complex in vivo 
systems.  In these instances, the target antigens are often overexpressed in target tissue 
relative to normal tissues.  This differential expression affords the opportunity for 
successful selective targeting.  However, target expression, especially in vivo, can be 
modulated by a number of environmental factors including cytokine exposure and 
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physical cellular damage.  Due to these constraints, and others, prior knowledge of target 
expression is required to reliably select suitable targeting agents and to predict the 
success of any targeting approach.  Further quantitative evaluation of native and 
modulated expression of a particular target antigen can be instrumental in assessing the 
improvement in therapeutic index provided by a specific approach.  Chapter 2 of this 
dissertation describes the analysis of one such target receptor in an in vitro environment 
and explores the advantages of quantitative target analysis relevant to targeted delivery. 
Once the target antigen has been selected, appropriate targeting elements must be 
implemented to mediate specific interaction with the target site.  Often, small molecule 
and peptide ligands have been employed to mediate these specific environmental 
interactions.  However, conjugation of molecules to the particle surface can alter both the 
activity of the ligand and the characteristics of the base particle, often in unpredictable 
ways.  Thus, incorporation of these ligands into nanoparticle constructs has not yet seen 
widespread application.  Nonetheless, new conjugation approaches enable the synthesis 
of nanoparticle constructs that retain both the bioactivity of the attached ligands and the 
properties of the underlying nanostructure.  Chapter 3 details the synthesis and in vitro 
analysis of one such construct and highlights the utility of specific ligand interactions in 
targeting nanoparticles to cellular proteins. 
One historic drawback to the use of molecular targeting agents, even when 
operating with ideal target receptors, is target binding specificity.  Previous approaches 
using a range of small molecule and peptide targeting agents have been plagued by 
nonspecific interaction with nontarget tissues and specific binding to nontarget tissues 
that express the antigen target.  One approach to limit these interactions is modification 
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of the construct surface with PEG polymers.  The effectiveness of PEG in reducing 
nonspecific interactions has been well documented, and has been utilized in several 
commercial therapies (e.g. Neulasta™, PEG-INTRON®, Somavert®).  One variation of 
this approach (described in detail in Chapter 4) is the application of a cleavable passive 
PEG “mask” to the targeting construct.  In the absence of specific enzymatic activity, the 
targeting construct appears as a PEGylated nanoparticle with low nonspecific 
recognition.  Specific proteolytic modification can then be harnessed to unmask the 
construct, thus removing the passivating PEG layer and activating the previously 
concealed targeting system. 
To achieve maximal target selectivity of the envisioned proximity activated 
targeting (PAT) construct (described in the Future Work section of this document), both 
targeting elements (specific enzyme activity and target protein expression) must be 
simultaneously present to effect specific interaction of the ligand with the target tissue.  
In this system, initial proteolytic cleavage and liberation of the passivating PEG layer 
enables access to the peptide targeting agent previously concealed near the NP surface.  
Once unmasked, the targeting ligand can then participate in specific binding interactions 
with target proteins in the area.  Thus, the colocalization of two distinct, but separate, 
targeting mechanisms greatly reduces the probability of construct interaction with 
nontarget sites. 
The approaches developed in this work have the potential to establish a NP 
targeting system with the sensitivity, efficacy, and modularity previously unavailable in 
similar targeting strategies.  The multi-layer targeting strategy employed in this system 
integrates the advantages of multiple targeting approaches while implementing measures 
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to overcome their various limitations.  The ease of detection (via fluorescence) make the 
model system described here a powerful and readily accessible detection alternative.  In 
addition, the inherent construct modularity enables customization of the targeting system 
to adapt to different targets, detection modalities, and delivery strategies.  These 
advancements have the potential to provide a versatile system capable of providing 
features for targeted binding, imaging, biosensing, and therapeutic payload delivery in a 
single nanoscale particle. 
 
1.2 Specific Aims 
Aim I – Characterize peptide and receptor properties and interactions in in vitro cellular 
models. 
I have completed a detailed quantitative study of the CD13 (aminopeptidase N) 
protein on the surface of HT-1080 cells in vitro.  Cell surface proteins were labeled with 
fluorescently tagged mAbs and results quantified via flow cytometry.  Native receptor 
density as well as the kinetic cellular response to sublethal radiation doses and 
endogenous cytokines TNF-α and TGF-β1 were measured and quantified to provide a 
more complete portrait of the CD13 protein under neoplastic conditions.   
 
Aim II – Characterize NP-linked ligand binding to target cellular receptors in in vitro 
tissue models. 
I have synthesized a mobile NP construct capable of specific binding to proteins 
on the surface of tumor cells.  The effects of surface modification on NPs were studied, 
including the effects of PEG coating and ligand attachment.  To enable specific targeting, 
a peptide (CNGRC) recognizing the CD13 receptor was conjugated to the NP surface.  
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NP-ligand binding was visually assessed by fluorescence microscopy, with subsequent 
quantitative analysis flow cytometry.  A new method was also developed and applied to 
calibrate flow cytometry fluorescence measurements for quantitative analysis of NP 
binding to the cell surface. 
 
Aim III – Investigate NP-linked tumor-specific cleavable construct in in vitro models. 
I have developed a NP construct capable of modification by enzymes in the local 
tumor environment.  Successful synthesis and specific cleavage of a PEG-peptideMMP7-
PEG proximity activated (PA) proteolytic peptide construct was demonstrated in an in 
vitro environment.  Based on this evidence, a NP-PA construct capable of specific 
cleavage by the MMP-7 enzyme was developed, synthesized, and characterized.  
Quantitative measurements and analysis of construct performance were assessed by gel 
electrophoresis and fluorescence spectroscopy. 
 
1.3 Background and Significance 
Despite the substantial resources allotted to cancer study and prevention each 
year, an estimated 1.3 million people in the United States will be diagnosed in 2004, with 
over 560,000 deaths attributable to the disease (5).  On top of the immense cost to human 
life, the NIH estimates $64,200,000,000 in direct medical costs for cancer treatment in 
2004 (5).  The continued prevalence of cancer diagnosis and death, as well as the soaring 
medical costs associated with cancer management, demand new efforts to develop novel 
detection and treatment strategies.  Current anti-tumor chemotherapeutic agents are 
plagued by inherent shortcomings, including rapid clearance of the agents from the blood 
circulation, poor distribution to tumor sites, and toxic side effects on normal tissues.  We 
 6
employ several elements of nanoscale particle design to overcome limitations of 
conventional cancer detection, reporting, and treatment, and to facilitate strategies to 
significantly reduce morbidity associated with the disease. 
 
 
1.3.1 Treatment Strategies are Limited by Tissue Biodistribution 
 The in vivo distribution pattern of macromolecules and NPs is a major obstacle 
limiting the design and implementation of particulate drug delivery systems.  NP delivery 
in vivo is limited on both circulation and a tissue levels.  Particle diameter variation 
within the nanoscale range strongly affects both the blood circulation time as well as the 
bioavailability of particles within the body (6-8).  Mechanical filtration in the pulmonary 
capillary beds and the superficial and juxtamedullary glomerular tissue of the kidney 
limits the maximum particle diameter to less than 3µm, although particle trapping is 
significant with diameters above 1µm (9).  Endocytosis or other removal by immune or 
humoral response also modulates circulation duration and must be considered in particle 
design (10,11).  To achieve systemic interrogation, the construct must be capable of 
cardiovascular extravasation and subsequent tissue transport of at least 50% of the 
average intercapillary distance.  Thus, construct mobility must be on the order of 50µm 
or less for most tissues.   
 
 
1.3.2 Smaller Particles for Ubiquitous Tissue Delivery 
Particle diameter strongly modulates tissue biodistribution.  Generally, particles in 
the nanoscale range are preferable, as their small diameter allows transport through size 
restrictive structures in all physiological compartments.  In vitro, particle size 
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significantly affects cellular and tissue uptake, and in some cells only submicron size 
particles are taken up efficiently but not larger size microparticles (12).  In vivo, 
structures as large as 70nm have been observed to passively move through the interstitial 
space.  Furthermore, the diffusion of nanoscale structures 10-20nm in size in tumor tissue 
of varying densities is sufficient to move the structures from 400-800µm over the course 
of one hour (13).   
Semiconductor QD nanocrystals coated with an amphiphilic polymer vary in 
diameter from 2 to 7nm, while PEG surface modification contributes an additional 7 to 
21nm to the QD diameter, depending on molecular weight (14).  Thus, total construct 
diameter is predicted to range from 9 to 28nm.  Molecular flexibility and relatively low 
surface concentration of the PEG, however, provide a deformable layer surrounding the 
rigid nanocrystal core, decreasing the effective particle diameter and improving 
biotransport through size restrictive structures.  The overall diameter of PAT NPs 
presumably allows their implementation as a versatile delivery construct, capable of 
significant interstitial mobility and intracellular trafficking. 
 
 
1.3.3 Therapeutic Efficacy is Limited by Nonspecific Delivery of Therapeutics 
 For more than five decades, chemotherapy has been the main modality for 
systemic treatment of advanced and metastatic cancers (15).  However, therapeutic 
approaches to cancer treatment are often limited by intrinsic or acquired multidrug 
resistance of tumor cells and toxicity caused by nonspecific delivery of 
chemotherapeutics to normal cells (16).  Administration of bolus systemic doses of 
highly potent drugs to overcome these obstacles often triggers side-effects so intense that 
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patients must discontinue therapy before the drugs have a chance to eradicate the cancer 
(17).  The current generation of targeted therapies has not yet solved this issue, as highly 
specific targeting of existing tumors and emerging neoplasia through a single recognition 
mechanism has not generally been successful (18,19).  Nonspecific binding and specific 
binding to nontarget tissues compromise the therapeutic index of small molecule, 
ubiquitous cancer targeting ligands and limit their applicability and efficiency as primary 
chemotherapeutic agents.   
 
 
1.3.4 Enhanced Specific Delivery Towards Improved Treatment/Outcomes 
Increased distribution of therapeutics to target areas can occur by direct injection 
of the therapeutic construct into the tumor volume or by increased specific targeting of 
the construct to the tumor.  Enhanced delivery and distribution of therapeutics within the 
tumor volume can be achieved by both passive and active targeting principles.   
 Passive targeting reduces the nonspecific interaction with nontarget sites such as 
the RES, while active targeting involves increasing the affinity of the delivery system for 
the target site.  PAT delivery systems are intended to minimize undesirable interactions 
with nontarget tissues via a passivating hydrophilic PEG surface coating.  This coating 
serves to limit recognition and clearance by the RES and other nontarget cells as well as 
to protect the inner construct and payload from enzymatic degradation.  PAT systems 
also employ two levels of active targeting (cleavage by MMP-7 and specific targeting of 
the CD13 receptor by the NGR peptide) to maximize specific binding to target tissue.  
This two-layer targeted system increases the effective sensitivity of the construct by 
keeping the passive PEG coating intact and revealing the targeting ligand only in the 
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immediate proximity of the tumor (Figure 1.1).  Thus, PAT constructs are expected to 
achieve greater target selectivity over both conventional and single-modality targeted 
chemotherapeutics. 
 
 
1.3.5 Prior Evidence of Molecular Targeting of Nanoparticles 
 
 Enhanced targeting of intravascularly delivered NPs has been reported in several 
recent publications.  Passive targeting of QDs in mice is detailed by the work of Ballou et 
al. (20).  This study suggests that manipulation of NP surface coating can control both 
serum lifetime and the pattern of tissue deposition in vivo.  In particular, long-chain PEG 
surface coatings (MW = 5 kDa) were found to be superior to shorter PEGs at reducing 
nonspecific uptake of NPs by the RES and binding to nontarget tissues such as the liver, 
lungs, and spleen.  However, Ballou et al. incorporate no active targeting measures into 
the NPs studied here, nor do they demonstrate a propensity for these NPs to accumulate 
preferentially in tumor tissue. 
Oyewumi et al. offered additional evidence of passive targeting by studying the 
biodistribution and tumor retention of folate-PEG coated NPs (21).  These particles were 
shown to exhibit prolonged blood retention properties indicating reduced uptake by the  
RES.  Additionally, significant NP retention was seen in the liver, spleen, and lungs.  
However, it is unclear whether this accumulation was due to mechanical filtration or 
nonspecific interaction as the NPs utilized were on the order of 100nm in diameter.  
Biodistribution studies indicate that any tumor accumulation was likely due to passive 
targeting, as the active targeting component (folate ligand) demonstrated no benefit over 
passive PEG coatings.   
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C D 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1.  Representative structure of PAT nanoparticle.  A. A PEG coating conceals the targeting ligand 
(blue) and passivates the surface of the native particle.  B. Proteolytic action of MMP-7 (purple), secreted 
by tumor, cleaves the peptide bridge (green) revealing the targeting ligand.  C. MMP-7 and cleavage 
fragments diffuse away.  D. Ligand-targeted construct is revealed only in proximity to tumor, enabling 
specific binding to target sites. 
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Active targeting and gene delivery of 40-50nm cationic NPs was studied in the 
work of Hood et al (22).  This work reports selective targeting to receptor-positive cells 
in vitro as well as to tumor vasculature in vivo resulting in significant reduction of tumor 
volume after treatment with targeted NPs.  This work, however, provides no 
measurements detailing the delivery of NPs to target or nontarget sites.  Hood et al. relied 
on gene expression and tumor regression as a measure of success; they did not attempt to 
offer qualitative observations or to quantify the delivery or biodistribution of their 
targeted NPs.   
Effective targeting and tissue biodistribution can be improved through 
incorporation of both passive and active targeting components.  Gao et al. showed that 
QDs can be successfully targeted to cancer cells under in vivo conditions (23).  NPs used 
in this study contained both a PEG coating and an active targeting mAb ligand.  Targeted 
NPs exhibited increased performance over NPs with only a PEG coating as they 
extravasated, and were delivered to and retained by tumor xenografts in vivo.  However, 
nonspecific liver and spleen uptake was still apparent with these particles.  It is unclear 
whether this accumulation resulted from mechanical filtration due to the relatively large 
size of the mAb targeting ligand (~150 kDa), immune recognition and clearance of the 
mAb ligand, or through some other unknown mechanism. 
 Ruoslahti et al. further demonstrated both active and passive targeting principles 
in a single NP with a coating of coadsorbed targeting peptide and PEG (24).  These NPs 
successfully targeted vascular sites in vivo (active targeting) while significantly reducing 
uptake by the RES and accumulation in the liver and spleen (passive targeting).   
However, only qualitative visual data garnered from tissue sections was presented to 
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support these claims.  Furthermore, the particles were targeted only to vascular tissue and 
failed to accumulate in the tumor volume.  No negative control or blocking data was 
presented, leaving concerns regarding nonspecific binding due to the targeting peptide as 
well as the stability of the NPs under in vivo conditions. 
 NP targeting described in the literature predominantly focuses on easily accessible 
tissues such as blood and lymph vessels, liver, spleen, kidney, and lung.  Active targeting 
of NPs to deep tissues (including tumors) is not widely reported beyond particle 
accumulation due to passive targeting and leaky tumor vasculature. 
  
 
1.3.6 Prior Evidence of Successful Implementation of Tumor-Specific Cleavable 
Constructs 
 Compounds cleavable by tumor-specific enzymes have been incorporated into 
many structures ranging from in vivo imaging constructs to chemically modified drug 
structures. 
The development of tumor-specific molecular imaging constructs cleavable by 
MMPs has been reported by Zucker et al. (25), Bremer et al. (26,27), and McIntyre et al 
(28,29).  The latter study reports the synthesis of a proteolytic beacon for in vivo imaging 
of the MMP-7 enzyme.  McIntyre et al. found that this structure was successfully cleaved 
by MMP-7 in in vitro assays as well as in vivo in mouse xenograft tumors expressing the 
MMP-7 enzyme.  Cleavage was shown to be specific for the MMP-7 enzyme, with a 
resulting kcat/Km at least 13-fold larger than for other MMP enzymes tested.  The basis of 
the MMP-7 specific peptide substrate utilized by McIntyre et al. (RPLALWRS) is 
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employed in the current studies described in this dissertation as the cleavable portion of 
the NP delivery system. 
 Multiple studies have reported the incorporation of tumor-specific cleavage into 
the structural design of drug molecules in the form of prodrugs.  In one such reference, 
Liu et al. describe a doxorubicin prodrug capable of specific cleavage and activation by 
the tumor-associated enzyme legumain (30).  Doxorubicin was successfully modified 
with a legumain-cleavable peptide substrate to form a prodrug with significantly reduced 
toxicity.  The cytotoxicity of this structure could be recovered by cleavage of the arginyl 
peptide by tumor-associated legumain.  The work of Liu et al. demonstrates the 
feasibility of tumor-specific enzyme interaction as a means of modifying the physical 
structure of delivered drugs, and possibly of delivered NP and particulate drug carriers. 
 Incorporation of tumor-specific cleavable linkers into structures for drug delivery 
has been documented by Suzawa et al (31,32).  Immunoconjugates of the antitumor drug 
adriamycin (ADM) were synthesized by conjugation to a targeting mAb through a 
cleavable PEG-dipeptidyl linker.  Specific cleavage of this linker was demonstrated as 
well as antigen-specific targeting of the conjugate to the cell surface (via the attached 
mAb).  While this study does report specific cleavage of the dipeptidyl linker by model 
enzymes, it does not demonstrate release of active drug at the cell surface or by enzymes 
released by cells in vitro.  It is unclear whether this construct can be cleaved by tumor-
specific enzymes or at enzyme levels produced by tumors in vivo.  Furthermore, concerns 
remain as to whether the ADM released by construct cleavage exhibits sufficient 
cytotoxicity compared to unconjugated ADM. 
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 Literature citations of tumor-specific cleavable constructs focus mainly on 
molecular imaging of enzyme activity and drug activation in vivo.  Incorporation of these 
constructs into NPs or their application to target NP-based therapeutic delivery systems 
has not yet been reported in the literature. 
 
 
1.3.7 Novel Aspects and Improvements upon Prior Efforts 
 
 We have assessed NP accumulation and specific delivery in in vitro systems 
based on established fluorescence and cell viability protocols, coupled with quantitative 
imaging modalities.  The PAT construct described here combines the successes of prior 
targeting efforts, producing a novel bionanoparticle that offers inherent desirable 
advantages in the realm targeted therapeutics and biosensing.   
The strength of this approach lies in the ability to integrate detection, imaging, 
and treatment characteristics into a single particle.  The nanocrystal base of the construct 
is a flexible platform that affords opportunities for attachment of a range of molecular 
structures ranging from specific targeting ligands to small molecule chemotherapeutics.  
Furthermore, the relatively large surface area of the nanocrystal base (when compared to 
single molecules) allows the attachment of multiple copies of both the targeting ligand 
and therapeutic molecule, or of multiple distinct targeting mechanisms.  This 
characteristic confers multivalent binding capability to the NP construct as well as the 
ability to deliver multiple therapeutic molecules in a single package.  Envisioned, but not 
studied here, are extensions to the NP construct to enable high sensitivity, high resolution 
in vivo imaging of emerging neoplasia and established tumors.   
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Previous studies have outlined the importance of both passive and active 
processes on the success of specific targeting.  The PAT construct contains elements to 
maximize each of these targeting processes.  A passivating PEG barrier is employed to 
minimize nonspecific interaction and specific interaction to nontarget tissues.  Two 
independent recognition mechanisms have also been described for integration into the 
PAT particle to maximize active targeting of the construct: local MMP-7 secretion and 
expression of the target receptor on the cellular surface.  The requirement for local 
proteolytic cleavage to reveal the targeting ligand allows the PEG barrier to remain intact 
until the particle encounters a target area, presumably enabling the construct to actively 
target only in areas of increased MMP-7 enzyme concentration. 
Most targeted applications focus mainly on vascular or other easily accessible 
targets.  The nanoparticle system described here should interrogate all potential target 
body compartments via a single administration route.  To achieve this aim, the NP 
construct must exhibit efficient extravasation and interstitial transport.  Based on prior 
evidence, NP diameter is a strong modulator of these characteristics.  The overall 
diameter of the NP construct is chosen to minimize rapid, nonspecific clearance of the 
NPs while maximizing extravasation and interstitial transport of the constructs.  Small 
particle size and enhanced biodistribution characteristics proffer the ability to treat 
established primary tumors, emerging neoplasia, and distant metastases. 
 Once an effective strategy is developed for the treatment of a single type of 
tumorigenic target, tumor phenotype or physiology often prohibits adaptation of the 
therapy for treatment of other malignancies.  The NP delivery system described here 
contains multiple levels of modularity to enable an array of NP constructs to significantly 
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impact cancer therapy.  The current strategy is modular in four dimensions: (1) different 
tumor-specific small molecule targeting ligands can be employed, (2) different peptide 
substrates for enzymatic activity can replace the MMP-7 peptide, (3) a range of 
therapeutic molecules can be delivered and (4) different nanoparticle, nanocrystal or 
molecular structures can be used as the core of the construct.  Thus, the ideal component 
can be chosen from all four categories to create a NP delivery system tailored to the 
purposes of the specific application. 
 
 
1.3.8 Imaging of NP accumulation in target cell populations 
 
 The intense fluorescence and photostability of QD nanocrystals allows high-
sensitivity detection of NP accumulation in vitro.  These fluorescence characteristics 
enable high-resolution fluorescence microscopy and confocal microscopy imaging of 
labeled cells and internal cell structures as well as quantitative fluorescence 
measurements via fluorescence spectroscopy and flow cytometry. 
 The use of high-resolution fluorescence imaging allows determination of the 
intracellular fate of targeted NPs in in vitro systems and visualization of NP surface 
binding and internalization.  Fluorescence spectroscopy and flow cytometry enables 
quantitative analysis and validation of NP accumulation and binding.  Quantitative 
fluorescence measurements also provide kinetic NP binding and proteolytic cleavage 
measurements to further characterize the efficiency of the NP construct. 
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1.3.9 Overcoming nonspecific delivery of therapeutic agents 
 Due, in part, to the historic difficulties encountered in specific targeting, no single 
targeting strategy has been able embody the “magic bullet” concept envisioned by Paul 
Ehrlich at the turn of the 20th century.  Obstacles such as nonspecific binding and specific 
binding to nontarget tissues continue to plague most single-modality targeting strategies.  
The relative lack of effective targeted therapies in the marketplace reveals the need for 
new and innovative approaches to this problem and presents an opportunity to make a 
significant contribution to this effort.   
Autonomous unmasking of the targeting ligand only in the proximity of a cellular 
target is the critical feature of the PAT construct.  Upon administration, PAT NPs exhibit 
a passive, non-immunogenic PEG barrier.  Previous studies have shown PEG conjugation 
to increase particle circulation time by minimizing nonspecific clearance by the RES as 
well as nonspecific retention of particles in the liver and spleen (20,33).  This behavior is 
expected to extend to particles in the interstitial space as well, although the body of 
evidence regarding interstitial NP transport and recognition is limited.   
Local proteolytic cleavage removes the passivating PEG layer to reveal a site-
specific targeting ligand, enabling active targeting of the NP to target cellular receptors.   
The independent action of the recognition mechanisms built into the PAT NP ensures that 
both enzymatic activity and target receptor expression must be present to elicit active 
targeting of the construct.  This independent dual-layered targeting approach combines 
successful elements of previous studies to maximize site-specific targeting of the PAT 
NP while keeping side effects caused by nonspecific interactions to a minimum. 
 
 18
1.3.10 Background and Significance: Aim I – Characterize peptide and receptor 
properties and interactions in in vitro cellular models. 
 
The role of the CD13 receptor in biological processes 
 CD13 is a zinc-binding protease belonging to the family of proteins known as 
ectoenzymes.  This enzyme is constitutively expressed in a variety of tissues, with its 
functional role dependent on location.  CD13 is highly expressed in the intestinal brush 
border where it participates in the final hydrolysis of ingested proteins (34).  It is also 
expressed in the kidney, and to a lesser extent in the spleen and brain, among other 
tissues.  Functions in these tissues range from degradation of neuropeptides and cytokines 
to antigen processing (35). 
 CD13 has been shown to take on a different role in tumor physiology.  Under 
neoplastic conditions, CD13 is reported to react with leukemic blasts of most acute 
myeloblastic leukemias (36,37), and has been utilized extensively as a marker for 
leukemia typing (38,39).  This protein has been shown to promote tumor invasion and 
migration by active degradation and rearrangement of ECM components and promotion 
of angiogenesis.  CD13 has also been implicated as an auxiliary adhesion molecule, 
mediating cell-cell contact in melanoma colonies and adherence of metastatic breast and 
prostate carcinomas (40,41). 
 
NGR binding and differential expression of CD13 isoforms in vivo    
 The NGR motif has been identified via phage display as a tumor-homing 
tripeptide sequence selectively targeting tumor vasculature in vivo (42,43).  Additional 
studies identified CD13 as the receptor for this peptide motif (44).  Although CD13 
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expression has been reported in a variety of tissues, Curnis et al. have exhibited the 
existence of at least two distinct isoforms of this antigen (45).  Further investigation 
confirmed that the isoform found in tumorigenic cells and angiogenic blood vessels 
functions as a receptor for the NGR motif, while the isoform expressed in normal 
counterparts of these cells does not appreciably bind NGR conjugates.  CD13 
overexpression has been measured in both tumor cells and angiogenic blood vessels 
(46,47), providing an appealing and accessible target for directed therapy. 
 
Receptor expression in response to environmental factors 
 Mammalian cells express a wide variety of surface molecules ranging from 
enzymes to integrins, with a spectrum of expression profiles.  Some of these molecules 
are constitutively synthesized, while the expression of others can be increased, decreased, 
or induced de novo in response to various stimuli (48).  One study measured marked 
differences in surface expression of a host of surface molecules after exposure to 
endogenous factors including the proinflammatory cytokines IL-1β and TNF-α as well as 
to the well-characterized PKC activator PMA (49).  Exogenous factors such as ionizing 
radiation (50,51) and chemotherapeutics (52,53) have also been shown to strongly 
modulate gene and receptor expression in both in vitro and in vivo environments.  Cells in 
this “activated” state often exhibit large changes in the expression profiles of a number of 
surface receptors, leading to a functional state distinct from that seen under normal 
physiologic conditions. 
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1.3.11 Background and Significance: Aim II – Characterize NP-linked ligand binding to 
target cellular receptors in in vitro tissue models. 
 
Strategies to link functional molecular targeting ligands to the NP surface 
 
 Immobilization of functional proteins and peptides to solid supports has recently 
become an area of active research.  The use of NPs for this purpose has the inherent 
advantage of a large surface area to volume ratio (compared to molecular agents), 
allowing conjugation of a large number of active molecules.  Surface conjugation is 
further facilitated by the availability of multiple functional groups (typically carboxylic 
acid groups) on the surface of the QD, which can be utilized in a number of well-
characterized linking strategies.  Stable covalent conjugation of bioactive molecules such 
as enzymes (54,55), mAbs (56), peptides (57), and DNA (58,59) to the surface of NPs 
has been reported.  Many copies of small-molecule or short peptide ligands or DNA 
probes can be attached to the surface enabling multivalent QD-target binding.   
 
Quantifying cellular binding of NP-linked targeting ligand 
 Due to the intense fluorescence characteristics of the QDs utilized as the NP base, 
detection of cell-associated NPs is uncomplicated.  Similar strategies have been outlined 
for the fluorescence quantification of mAb binding to cell surface receptors (60,61).  The 
crux of these strategies is the measurement and quantitation of fluorescence changes in 
response to ligand binding.  Qualitative measurements can be made by visualization 
using fluorescence microscopy.  Total quantitative fluorescence measurements can be 
performed on a macroscopic level by simple spectroscopic detection using a fluorescence 
plate reader, or on the level of individual cells by flow cytometry.  Fluorescence 
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measurements are then converted to the level of ligand binding through the use of 
calibration methods. 
 
1.3.12 Background and Significance: Aim III -- Investigate NP-linked tumor-specific 
cleavable construct in in vitro models. 
 
Synthesis of the PA construct 
 Synthesis of the PA construct proceeds via established and well-characterized 
synthesis routes.  PEG molecules exhibiting a range of functional groups reactive toward 
the N- and C-terminal groups on the MMP-7 peptide can be readily purchased (Nektar 
Therapeutics).  Reactions proceed to completion using excess PEG, ensuring virtually 
complete conjugation of available MMP-7 target peptides.   
 Purification of the PA construct can proceed via several pathways.  Perhaps the 
fastest and simplest of these approaches is size exclusion chromatography.  As the 
individual components and intermediates have significantly smaller molecular weights 
than the final construct, size exclusion chromatography is expected to render a 
sufficiently pure product.  More sophisticated strategies such as HPLC and dialysis are 
available, but these approaches often require nontrivial time investments to optimize the 
separation parameters. 
 
Strategies to link PA constructs to the NP surface 
 Immobilization of PA constructs to the NP surface can be accomplished under the 
same conditions and linking strategies employed for targeting molecules (Aim II).  These 
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constructs employ the same functional groups as the targeting peptide molecules, 
allowing simultaneous and stoichiometric conjugation of both moieties to the NP surface. 
 
Measurement of PA construct cleavage 
Due to the nature of the cleavage product (LWRS-[Ahx]-C-PEG3400), detection of 
PA construct cleavage is nontrivial.  Total protein assays assessed by spectroscopic 
detection of fluorogenic amino acids (i.e. tryptophan) or traditional staining techniques 
may not be suitable due to the low amino acid content of the cleaved portion of the 
construct (5 amino acids, ~16% of the cleavage product by weight).  MALDI-TOF 
sampling can detect the generation and verify the molecular weight of cleavage products, 
although this method does not allow direct quantitation of cleavage extent (62).    
 Alternatively, the PA construct can be labeled with a fluorescent molecule (e.g. 
FITC or a FITC analog) to enable fluorogenic identification of cleavage products.  
Construct cleavage can be visualized qualitatively by changes in electrophoretic mobility 
of either the free molecule (in the case of non-QD conjugated construct), or of the entire 
QD construct (in the case of NP-linked PA construct), as well as by the generation of a 
distinct fluorescent band representing the labeled cleavage product.  Quantification of 
NP-linked PA construct cleavage can be assessed through a combination of the methods 
described above, or via spectroscopic measurement of liberated labeled cleavage 
products. 
 
MMP-7 expression in physiological and pathophysiological states 
MMP-7 expression in both normal and neoplastic tissue has been well-
characterized (63-65).  It is notable that MMP-7 is produced predominantly by cells of 
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epithelial origin, whereas most other MMPs are generally expressed by the underlying 
stromal cells including those residing in connective tissues or by migratory cells of the 
immune system (29).  Thus, in adenocarcinomas (the most common adult tumor type to 
arise from cells of epithelial origin) MMP-7 is expressed in the malignant epithelial 
component rather than in the surrounding stromal tissue.  Additionally, overexpression of 
MMP-7 has been reported in many tumors relative to the normal surrounding tissues 
(66,67).   
For tumor systems in which MMP-7 activity is known to modulate the course of 
the disease, MMP-7 is secreted even in the earliest stages.  Small, benign “precancerous” 
lesions, for example, exhibit MMP-7 secretion well before these lesions would be 
clinically detectable (68,69).  Furthermore, analysis of MMP-7 expression in human 
neoplasia revealed that the mRNA appeared in the surrounding normal tissue in only a 
few isolated cases (70).  The larger and more progressed these tumors become, the higher 
the MMP-7 levels tend to be.  This focused source of abundant extracellular MMP-7 is 
expected to provide ample activity for the in vivo application of PA NPs to cancer 
targeting.  
 
The role of MMP-7 in biological processes 
MMPs (including MMP-7) are a family of enzymes that have a role in tissue 
breakdown and remodeling during both normal (e.g. angiogenesis, gut innate immunity) 
and pathological (e.g. inflammation, tumorigenesis, metastasis) processes.  MMP-7 has 
been specifically implicated as an important facilitator of tissue remodeling due to its 
ability to cleave a variety of known substrates, including many ECM proteins and the 
latent forms of other MMPs (70).  In fact, overexpression of MMP-7 has been directly 
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correlated with enhanced tumorigenicity and tumor cell invasion using in vitro model 
systems (67).  It has been shown to be important in the progression of a number of 
tumors, notably those originating in the colon or in the breast (29).  Furthermore, MMP-7 
has proven to have diagnostic and prognostic value, as expression is associated with poor 
outcome in esophageal (71), colon (72), and pancreatic (73) cancers.  The overexpression 
and significance of MMP-7 in the tumor cascade make this enzyme an attractive target 
for site-directed drug delivery vehicles. 
 
QD toxicity 
 In vivo application of QD probes requires a comprehensive examination of both 
the short- and long-term toxicity of the QD core materials as well as any structures 
exhibited on the surface of the molecule; these studies are beyond the scope of this work.  
Most in vitro applications require only short-term toxicity studies on cultured cells, as 
experiments are often completed in a matter of hours or days. 
 Recent publications have examined the toxicity of QDs in both in vitro and in vivo 
environments.  Some studies have reported that QDs applied to immortalized cell lines in 
vitro results in no significant measures of toxicity (74,75).  In primary cultures and in 
vivo applications, QD toxicity was detected; however, QDs could be rendered nontoxic 
with appropriate surface coatings (76,77).  Long-term, degradation of QDs may result in 
liberation of the core materials of the particle.  However, as the studies described here do 
not occur over these time frames, short-term toxicity studies are expected to be sufficient 
to predict the response of cultured cells in vitro. 
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2.1 Abstract 
The CD13 protein is important in many functions ranging from degradation of 
neuropeptides to rearrangement of the basement membrane.  Due to its prominent 
overexpression in many cancers, CD13 has also gained interest as an attractive ligand for 
directed therapy studies.  While the function and performance of several CD13-specific 
targeting molecules has been examined both in vitro and in vivo, studies are often carried 
out without quantitative assessment of the target protein.  A lack of this data complicates 
further quantitative analysis and precludes a full understanding of the overall efficiency 
of specific targeting.  We performed a quantitative evaluation of CD13 on the surface of 
HT-1080 cells, a cell line utilized in several receptor-based studies, and compared this 
resting (unstimulated) value to that of cells stimulated in various manners.  Unstimulated 
HT-1080 cells strongly express CD13 at a level of 3,840,000 ± 70,000 (mean ± SD) 
antibody binding capacity (ABC)/cell (n = 4).  Following low-dose irradiation with 3Gy, 
receptor expression increases, peaking at a value of 6,300,000 ± 220,000 (n = 3).  The 
effects of TNF-α and TGF-β1 incubation were also monitored, with both cytokines 
resulting in marked increases in maximal CD13 expression relative to unstimulated 
controls to 7,250,000 ± 280,000 (n = 3) and 4,700,000 ± 270,000 (n = 3), respectively.  
Our results yield detailed information not available with experimental targeting data 
alone, and highlight the importance of conducting quantitative receptor analysis in 
conjunction with targeted delivery experiments. 
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2.2 Introduction 
Prototypical targeted therapeutic vectors have inherent advantages over traditional 
techniques in the areas of dose, safety, and overall efficacy.  In practice, however, these 
vehicles generally fail to realize their potential and suffer from poor targeting efficiencies 
and ineffective delivery (1).  One approach to improving the efficacy of these delivery 
devices is the addition of targeting complexes to the vector, thus promoting specific 
receptor-mediated binding and endocytosis of the construct.  Recent efforts have utilized 
this and other approaches in an attempt to improve the delivery and target specificity of 
genes and drugs to specific cell types (2,3,4,5).  For example, peptide and other tumor-
specific sequences have been utilized to target unique receptors on the surface of diseased 
cells, allowing the delivery of a relatively high concentration of drugs or genetic material 
to specific areas, increasing the efficiency and effectiveness of treatment (6-9).  
Molecular agents have also been included in several commercial therapies, including 
Herceptin, Glivec, and Avestin, to achieve site-specific delivery to target tissues in vivo.
Ligands including the Asn-Gly-Arg (NGR) motif in particular have been used to 
target treatments such as gene therapy and chemotherapy to the cell surface (10-12).  
Phage display studies identified this ligand as a tumor-homing tripeptide sequence 
selectively targeting tumor vasculature in vivo (13,14).  Further studies revealed the target 
of this sequence as the CD13 protein (15).  CD13 is expressed in a variety of tissues, with 
functions ranging from degradation of neuropeptides to rearrangement of the extracellular 
matrix (16,17).  Additional studies have discovered at least two distinct isoforms of this 
protein.  These experiments confirm that the isoform found in tumorigenic cells and 
angiogenic blood vessels functions as a receptor for the NGR motif, while that expressed 
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in the normal counterparts of these cells does not appreciably bind NGR conjugates (18).  
CD13 overexpression has been measured in both tumor cells and angiogenic blood 
vessels (19,20), providing an appealing and accessible target for directed therapy. 
Previous studies have shown that expression levels of cellular receptors and other 
proteins are strongly modulated by exposure to ionizing radiation (21,22,23) and various 
cytokines (24), although the extent of modulation is highly dependent on the protein-cell 
line pair.  Innate or inducible expression, as well as up- or down-regulation of these 
proteins may prove to be an important marker and target for tumor cells.  Furthermore, 
the phage display technique has uncovered a growing library of additional peptide 
sequences for molecular targeting to tumors and other specific cell types (25-28).  While 
these peptide sequences, along with other modalities, may be able to increase targeting 
efficiency, their intrinsic mechanism is governed by interaction with cell surface 
receptors.  Due to this constraint, a quantitative analysis of the relevant receptors is 
central to understanding and evaluating the effectiveness of the targeting moiety.  
Many studies have demonstrated the successful application of NGR-modified 
genes, drugs, and imaging agents to specifically target several cancer cell lines and 
vascular cells (29-31).  These NGR-directed delivery vehicles are designed to interact 
with specific surface proteins (CD13) to achieve effective site-specific binding.  This 
close surface association may modulate construct internalization and intracellular 
processing.  In fact, studies have shown that internalization is enhanced by high cell 
surface densities of integrin receptors (32).  Thus, these targeted constructs can be 
expected to be highly dependent on surface receptor concentration to achieve maximal 
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efficacy, and it is likely that cell types with varying numbers of these receptors would 
have differing intrinsic susceptibilities to targeted therapy.   
The correlation between relative receptor number and success of targeted delivery 
has been demonstrated in previous studies using traditional FACS analysis, although 
absolute quantitative measurement of the receptor number was not performed (33-35).  
The FACS measurements employed in these studies yields only uncalibrated fluorescence 
values for whole cells, revealing the limitations of traditional FACS analysis.  Thus, it is 
not possible to translate the results of most previous targeting studies into meaningful 
measures intrinsically associated with cellular characteristics.  These results allow only a 
qualitative comparison between cell lines.   
Advances in quantitative flow cytometry, however, have allowed the power of 
this technology to be extended for use in quantitative experiments including surface 
receptor quantitation (36,37).  Standardized products such as the Quantum Simply 
Cellular (QSC) kit, among others, allow quantitative cellular measurements to be 
performed in a consistent manner by using calibrated microspheres.  With this 
quantitative data, targeting effects can be combined with quantitative receptor measures 
to distinguish differences in performance and intracellular trafficking of targeting 
systems.  This additional analysis can presumably identify subcellular mechanisms 
suitable for modulation to optimize the biological impact from targeting materials and 
methods. 
A quantitative evaluation of the receptor number on the target cell surface is 
essential for a comprehensive interpretation of targeted gene or drug delivery, as well as 
other receptor-based experiments.  A lack of this quantitative data precludes further 
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important analyses and modeling and makes direct comparisons between cell lines and 
targeting systems much less compelling.  Quantitative methods, such as the one 
employed in this work, are invaluable resources in understanding the mechanism(s) 
responsible for limiting intracellular delivery and trafficking of drugs or gene therapies.  
This information could prove to be a critical factor in the development of improved 
delivery strategies for existing therapies or in the design of new and effective therapies 
altogether.   
 
2.3 Materials and Methods 
 
 
2.3.1 Cell culture 
 
HT-1080 cells (human fibrosarcoma, ATCC CCL-121) were maintained and 
subcultured in complete culture medium consisting of minimum essential medium 
(MEM) supplemented with 10% fetal bovine serum, 2mM glutamine, 1.5 g/L sodium 
bicarbonate, 0.1mM non-essential amino acids, 1mM sodium pyruvate, and 1% 
antibiotics of penicillin-streptomycin-amphotericin.  All cells were maintained at 37°C, 
5% CO2, and 95% humidity for the duration of the study.   
For immunolabeling assays, cells were grown in 12-well plates (Becton-
Dickinson) containing 1ml/well supplemented medium.  Before harvest, adherent cells 
were washed with Ca++/Mg++ free phosphate buffered saline (PBS).  PBS was aspirated 
and 1ml of non-enzymatic cell dissociation solution (Sigma) was then added until the 
cells detached.  Cells were immediately transferred into labeled cytometer tubes and 1mL 
supplemented MEM was added to stop the dissociation reaction.  Cells were then pelleted 
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by centrifugation at 900×g and counted (Coulter Counter).  For each cell type, 1×106 cells 
were removed and used for the remainder of the immunolabeling protocol.  
 
 
2.3.2 Monoclonal Antibodies 
Mouse IgG1 WM15 clone R-phycoerythrin (R-PE) labeled anti-human CD13 
monoclonal antibody (mAb; Becton Dickinson) was purchased and used to screen HT-
1080 cells.  All antibody measurements were administered at the stock concentration 
delivered by the manufacturer.  Conjugation to R-PE allowed straightforward detection 
using the FL2 channel of a FACSCalibur flow cytometer (Becton Dickinson).  The same 
lot of antibody was used in all studies. 
 
 
2.3.3 Cell irradiation 
 
Irradiation was performed at room temperature using a Mark 1 irradiator with a 
Cs 137 source (JL Shepherd and Associates).  Subconfluent monolayers (~60% 
confluence) in 12-well plates (Becton-Dickinson) were irradiated with 3Gy at a dose rate 
of ~1Gy/min.  Immediately following radiation exposure, cells were returned to 37°C, 
5% CO2, and 95% humidity.  Cells were then harvested by incubation in non-enzymatic 
cell dissociation solution (Sigma) at 1, 3, 6, 12, 24, and 48 hours post-irradiation and the 
immunolabeling and quantification assays were followed as described below. 
 
 
2.3.4 Cytokine incubation 
 
 HT-1080 cells were seeded in 12-well tissue culture plates for exposure to either 
TNF-α or TGF-β1.  To achieve consistent final cell concentrations, individual wells were 
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seeded at varying cell densities depending on the incubation duration for each sample: 1-
day samples were seeded at ~50% confluence, 3-day samples at ~25% confluence, and 6 
day samples at ~10% confluence.  Subconfluent monolayers were incubated in complete 
culture medium as previously described, supplemented with either 100ng/ml TNF-α 
(Sigma) or 10ng/ml TGF-β1 (Sigma).  Culture medium was changed every 24h to ensure 
relatively constant cytokine concentrations during the course of the experiment.  Cells 
were then harvested by incubation in non-enzymatic cell dissociation solution at 1, 3, and 
6 days and assayed for CD13 expression. 
 
 
2.3.5 Immunolabeling assay 
 
For initial studies, mAbs were utilized at the manufacturer’s recommended 
dilution (20µL/106 cells) in PBS in a direct immunofluorescence assay.  Cells 
(approximately 1x106) were preincubated for 5 min in PBS supplemented with 1% 
bovine serum albumin to block nonspecific binding.  Cells were then incubated with 80µl 
of mAb solution for 45 min at 4°C.  After washing twice with fresh PBS cells were 
suspended in 1ml PBS for flow cytometric analysis.  Saturating mAb conditions were 
confirmed by increasing the mAb concentration until no additional fluorescence (as 
measured by flow cytometry) was seen with increasing dose.  The initial mAb 
concentration was found to be sufficient to saturate all available CD13 sites on the cell 
surface.   
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2.3.6 Flow cytometry calibration 
 
Flow cytometry fluorescence measurements were calibrated by utilizing 
standardized Quantum Simply Cellular microspheres (QSC; Bangs Labs).  This assay is 
based on the linear relationship between measured mean fluorescence intensity (MFI) and 
surface receptor expression level measured as antibody binding capacity (ABC).  The 
QSC kit contains four uniform microsphere populations of the same size with various 
known binding capacities to mouse monoclonal IgG antibodies (2693, 27795, 439497, 
and 681322 ABC), along with a blank population that has no specific binding capacity 
for mouse IgG. 
1 drop (~50µl) of QSC microspheres was incubated with the manufacturer’s 
suggested concentration of mAb in PBS for 60 min at room temperature.  The sample 
was then washed twice, analyzed by flow cytometry, and the results used to calculate a 
standard curve by plotting the MFI for each microsphere population (FL2 intensity) 
against its known ABC level.  Saturation of the IgG binding sites on the surface of the 
microspheres was confirmed by treatment with increased concentrations of mAb until no 
additional fluorescence was measured.  The original mAb concentration was sufficient to 
saturate all mAb binding sites on the QSC microspheres. 
 
 
2.3.7 Surface protein quantification 
CD13 quantification was performed by determining the mean fluorescence of 
both control and mAb treated cell populations.  The control fluorescence was then 
subtracted from the fluorescence of the treated cells to determine the fluorescence shift 
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caused by mAb binding.  This fluorescence shift was compared to the regression curve 
obtained from the QSC microspheres to determine the ABC level of the cell population. 
 
 
2.3.8 Flow cytometric analysis 
 
All samples were analyzed on a FACSCalibur (Becton Dickinson) that delivers an 
excitation beam at 488nm with an argon laser.  Cell or microsphere controls were 
measured and gates were drawn to define whole cell and sphere populations.  Further 
data collection was then based on these gates.  All samples (cells and QSC microspheres) 
were collected using identical instrument settings to allow direct comparison of measured 
values.  For each sample, 20,000 gated events were collected by list-mode data, 
consisting of forward scatter, side scatter, and fluorescence emissions FL1 (530 nm), FL2 
(585 nm), and FL3 (650 nm).  WinList software (Verity Software House) was utilized to 
determine the linear mean (MFI; mean FL2 intensity) of each cell and QSC microsphere 
population. 
 
 
2.3.9 Statistics 
Statistical significance of experimental populations was assessed using an upaired 
t-test and determined by SigmaStat (Jandel Scientific Software).  Differences were 
termed significant for p < 0.05. 
 
2.4 Results 
HT-1080 cells express the CD13 protein on their surface at relatively high levels.  
Flow cytometry was utilized to quantify changes in cell-associated fluorescence after 
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addition of anti-CD13/R-PE mAb (Figure 2.1).  A distinct increase in FL2 emission 
intensity was observed after treatment with the labeled mAb, indicating strong interaction 
of the mAb with the cell surface.  Control, untreated HT-1080 cells had a mean FL2 
intensity of 1.3 arbitrary units (a.u.), while cells treated with the anti-CD13/R-PE mAb 
had a mean intensity of 922.4 a.u.  This shift of 921.1 a.u. suggests significant antibody-
cell surface interaction that can be quantified by the calibration method applied in this 
work. 
The QSC assay yields a linear relationship relating fluorescence changes to 
surface receptor concentration.  To perform receptor quantitation, QSC microspheres 
were incubated with anti-CD13/RP-E mAb and analyzed by flow cytometry utilizing the 
same settings used in cell experiments.  Mean fluorescence measurements were obtained 
for each microsphere population and data was used to calculate a standard curve relating  
FL2 fluorescence intensity and the known ABC of each microsphere population (Figure 
2.2).  The standard curve demonstrates the linear relationship between receptor 
concentration and fluorescence intensity obtained from these values.   
Flow cytometry results, coupled with the QSC assay, can be used to quantify mAb 
binding to the cell surface.  The standard curve obtained from the QSC microspheres was 
used to relate the measured FL2 shift of mAb treated cell samples to the corresponding 
ABC level.  The calibrated CD13 expression levels for the HT-1080 cells studied here are 
a direct linear transformation of the uncalibrated fluorescence values shown in Figure 2.1.  
These cells exhibit a fluorescence shift of 921.1 a.u. as a result of anti-CD13/R-PE 
binding, correlating to a mean CD13 expression level of 3,840,000 ± 70,000 ABC/cell (n 
= 4).  
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Figure 2.1. Incubation of HT-1080 cells with anti-CD13/R-PE mAb results in a significant shift in 
fluorescence intensity in the FL2 measurement range.  Control, untreated HT-1080 cells (dashed line) 
generate low autofluorescence in the FL2 wavelength range when measured by flow cytometry.  Incubation 
of the cells with R-PE labeled mAb (solid line) produces a unimodal cell population with an average FL2 
intensity more than 1000-fold greater than that of untreated HT-1080 cells, presumably correlated with high 
expression levels of the CD13 antigen on the cell surface. 
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Figure 2.2. The correlation relating mean fluorescence intensity (MFI) measured by flow 
cytometry to antigen expression levels (measured as ABC) results in a highly linear relationship.  QSC 
microspheres were incubated with the manufacturer’s recommended mAb concentration (20µl mAb, solid 
circles).  A standard curve (solid line) produced from the relationship between MFI and ABC yielded a 
linear relationship (R2 = 0.9992) enabling a straightforward and accurate conversion of raw MFI data to 
ABC/cell.  Insignificant modulation of the MFI:ABC relationship resulted from doubling the 
manufacturer’s recommended mAb concentration (40µl; open squares), suggesting that the microspheres 
were saturated at the 20µl dose.  n = 3 for each mAb concentration.  Error bars for the 40µl concentration 
have been suppressed to ease visualization. 
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 Low-level radiation exposure results in an extensive increase in CD13 expression 
on the surface of HT-1080 cells.  An increase in CD13 surface expression was detected 
by flow cytometry up to 48 hours after low dose irradiation (Figure 2.3).  CD13 
expression decreased transiently within 1h of irradiation at 3Gy, followed by the 
induction of a prolonged significant increase beginning 6h after irradiation.  Receptor 
concentration in irradiated cells continued to rise up to 24 hr after stimulation, reaching a 
mean value of 6,300,000 ± 220,000 ABC/cell (n = 3).  This rise in CD13 expression 
appears to peak at times >24 hr, as expression begins to decrease slightly at the 48h mark 
to 5,670,000 ± 110,000 ABC/cell (n = 3). 
 Exposure to the cytokines TNF-α and TGF-β1 modulates CD13 expression on 
HT-1080 cells.  Both compounds had statistically significant effects, although incubation 
with TNF-α resulted in markedly increased protein levels over both resting and TGF-β1  
stimulated HT-1080 cells (Figure 2.4).  After 24h, both cytokines caused a small but 
measurable increase in CD13 expression compared to control, unstimulated cells.  Effects 
of TGF-β1 appear to peak after this timepoint, reaching a maximum CD13 value of 
4,700,000 ± 270,000 ABC/cell, as no statistically significant increases are measured with 
continued incubation.  HT-1080 cells maintained these increased CD13 levels for the 
duration of the experiment.  TNF-α modulation continues to increase after 24h, elevating 
CD13 levels to 7,250,000 ± 280,000 ABC/cell at 48h.  This effect peaks after the 48h 
timepoint, with CD13 expression falling to 6,210,000 ± 260,000 ABC/cell after 72h.
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Figure 2.3. CD13 expression on HT-1080 cells increases significantly following low-dose irradiation with 
3Gy, as assessed by quantitative flow cytometry.  Functional protein surface concentration decreased 
transiently within 1h of irradiation, followed by the induction of a prolonged significant increase phase 
beginning at 6h post-irradiation.  Increased CD13 levels continue to rise up to 24h post-irradiation, 
reaching a peak value of 6,303,200 ± 216,800 ABC/cell (a 64% increase over unirradiated cells).  Values 
are mean ± standard deviation of three independent measurements (dotted line = CD13 expression of 
control, untreated HT-1080 cells).  All values are statistically different (p < 0.05) from unstimulated HT-
1080 cells (t=0). 
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Figure 2.4. Cytokine exposure results in significant modulation of CD13 expression on HT-1080 cells.  
Incubation with 10ng/ml TGF-β1 (open squares) resulted in a modest, but statistically significant increase 
(22%) in CD13 expression, peaking at 4,700,000 ± 269,900 ABC/cell after 72h.  100ng.ml TNF-α (solid 
circles) had a much larger modulatory effect, increasing CD13 levels to 7,248,100 ± 276,400 ABC/cell (an 
89% increase) after 72h.  Elevated CD13 expression levels were measured for both cytokines for the 
duration of the study (up to 144h incubation).  Values are mean ± standard deviation of three independent 
measurements (dotted line = CD13 expression of control, untreated HT-1080 cells).  Values for all 
timepoints are statistically significant from control (t=0) and between treatments (p < 0.05). 
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2.5 Discussion 
Although the importance of receptor concentration in modulating specific drug or 
gene targeting is well defined, few targeting studies have included direct target 
quantification.  Methods such as Western blotting and immunoprecipitation are typically 
used to confirm the presence of proteins on the surface of specific cell types (33,38).  
While such methods can confirm the surface presentation of specific proteins, they are 
not robust tools for quantitative assessments.  Traditional FACS analysis is also 
employed in a number of studies to verify the presence of specific proteins on the cell 
surface (33-35).  Although FACS analysis is intrinsically quantitative, uncalibrated 
results yield only a qualitative estimate of receptor presentation and complicate 
comparisons among instruments and reagents.  The methods used in the current study 
enable robust comparison of receptor presentations among multiple cell types and for 
various experimental and assessment conditions. 
Our studies (Figure 2.1), using traditional FACS analysis, confirm the presence 
and relatively high expression of CD13 on the surface of HT-1080 cells, in agreement 
with previous reports of high CD13 levels on these cells (39).  Fluorescence intensities in 
this system were well above the values measured in our previous quantitative studies for 
CD51 surface presentation on HeLa and other cell types (40), necessitating adjustment of 
fluorescence gain settings to accurately measure the labeled cell population. Large 
differences in fluorescence intensity distribution require optimization of FACS 
instrument settings that compromise comparisons in the absence of quantitative 
calibrations. 
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While fluorescence shifts measured by flow cytometry indicate functional protein 
presence on the cell surface and enable qualitative comparisons, they are not a direct 
measure of the number of receptors present on the cell surface.  Fluorescence intensity in 
this system is modulated by multiple of factors, ranging from the particular fluorophore 
used to specific instrument settings.  For example, fluorescence shifts measured in this 
study are far lower than those measured in our previous quantitative studies of receptor 
expression (~920 a.u. as compared to ~1400 a.u.) (40).  However, the smaller 
fluorescence shifts measured in the current study correlate to significantly higher 
expression values due to the specific, optimized, instrument settings utilized during data 
acquisition.  Thus, direct comparisons of raw fluorescence data are not necessarily 
accurate indicators of target surface number, especially across multiple systems, 
instruments, and reagents.  To ensure portability and reproducibility, FACS fluorescence 
intensity data must be correlated to physical values unaffected by experimental 
conditions. 
In the current study, fluorescence intensity measurements are standardized to 
enable conversion of measured intensity to the corresponding number of surface 
receptors.  The high degree of response linearity (in Figure 2.2) suggests that this 
calibration is free from artifacts, and provides a straightforward and reliable conversion.  
However, the fluorescence of some HT-1080 cells following mAb treatment (Figure 2.1) 
is outside the range established by the QSC standard curve (Figure 2.2).  The use of 
calibrated R-PE fluorescence standards, a common practice in flow cytometry, confirms 
the linear fluorescence response of this flow cytometer well beyond the established range.  
The fluorescence intensities of these standards span the measurable range, yielding a 
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linear relationship between fluorophore concentration and fluorescence intensity (MFI) to 
values approaching 10,000 MFI (data not shown).   
The ABC values obtained in this study indicate that CD13 is very highly 
expressed on the surface of HT-1080 cells (3,840,000 ± 70,000 ABC/cell), but not 
outside the measurement range established for cellular proteins.  Previous studies have 
shown that integrins and other proteins are highly expressed on many cell types in vitro, 
including expression levels of various surface markers from the low thousands to the low 
millions per cell (41).  The optimized methods used in this work yield functional protein 
quantitations on the cell surface that are more precise than many other techniques, 
reducing uncertainty in interpretation and subsequent calculational use of these values.  
Stimulation of HT-1080 cells with low dose ionizing radiation (3Gy) produced a 
significant increase in CD13 presentation on the cell surface (Figure 2.3).  This type of 
radiation-induced expression has been utilized in targeting to tumor endothelial cells and 
has been demonstrated to improve the efficacy of chemotherapy (42).  However, the lack 
of quantitative characterization of the endothelial cell response to x-ray complicates the 
application and limits optimization of increased targeting efficacy.  Elucidation of the 
kinetic and quantitative effects enables accurate identification of the temporal treatment 
strategy for optimum access to radiation-upregulated receptors and prediction of the 
likely success of the application.  The magnitude (64% increase) and duration (>48 hr) of 
the response measured in this and other (40) studies demonstrates the potential of 
radiation-induced tumor targeting as a strong potential candidate for therapeutic 
applications.  This result is particularly important in cases where standard treatment 
involves combination therapies such as radiation followed by administration of 
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chemotherapeutics (43).  Combination therapies utilizing elements directly targeted to 
tumor cells have the potential to improve the therapeutic index of conventional, 
nontargeted materials, but only if the pharmacokinetics of receptor availability are used 
to optimize the approach. 
CD13 presentation on the HT-1080 surface was also modulated by cell exposure 
to cytokines.  Both TNF-α and TGF-β1 produced measurable increases in CD13 
expression on the cell surface.  This response ranged from a modest but significant 
increase (22%) with TGF-β1 incubation, to a strong modulation (89% increase) by TNF-
α.  This result is consistent with previous reports of cytokine modulation of an array of 
cellular proteins (41,44).  This work is the first quantitative assessment of CD13 surface 
presentation modulated by TNF-α and TGF-β1 cytokines.   
Cytokine modulation of target expression is especially important in cases where 
these bioactive molecules are themselves utilized as therapeutic molecules.  Several 
studies have highlighted the utility of TNF-α as an antitumor agent (10,45,46).  These 
studies include several attempts at specific targeting to proteins expressed on the cell 
surface, including CD13.  Our results reveal that TNF-α significantly increases CD13 
expression in our in vitro system.  However, as shown in other studies, these effects can 
be either positive (increasing protein presentation) or negative (decreasing protein 
presentation) (41).  Thus, TNF-α (or other cytokines) delivered as therapeutic agents may 
have a direct effect on the efficiency of subsequent targeting through modulation of cell 
surface target presentation.  Knowledge of these interactions is likely to be critical in the 
development of effective therapeutic strategies and targeting approaches. 
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The role of cytokine modulation of cell surface receptor presentation in cancer 
biology is another application that can benefit from quantitative understanding.  The 
secondary effects on increased CD13 presentation on the cell surface is beyond the scope 
of this work, but conceivably contributes to the characteristics associated with a 
proliferative cell phenotype.  This study enables the quantitative comparison of CD13 
modulation by cytokine exposure in primary cells as a tool to explore the differential 
effects of this response. 
As evidenced by this study, receptor concentration can range widely, even within 
the same cell line when stimulated with various factors and to different degrees.  The 
wide range in CD13 expression levels measured within a given cell type subjected to 
various experimental conditions underscores the importance of quantitative receptor 
analysis in conjunction with targeted therapies.  The range in possible receptor 
concentrations is an important consideration in the design of targeted drug delivery 
vectors and the methods used for their evaluation and characterization.  Interaction with 
cell surface receptors is a prevalent strategy for specific cellular delivery in both in vitro 
and in vivo targeting studies.  Thus, direct receptor quantitation represents an important 
step in evaluating the fundamental efficiency of any receptor-targeting element.   
Many of the so-called “next generation” delivery systems are or will be designed 
to target specific cell surface markers, and therefore will be strongly dependent on 
receptor concentration for effective binding of the construct.  The effectiveness of these 
specific targeted vehicles, in turn, can only be determined with knowledge of the target 
availability (i.e. receptor concentration), and factors modulating target expression (e.g. 
irradiation, cytokine exposure).  However, surface interactions alone cannot dictate the 
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success or failure of targeted drug or gene delivery.  Other events, characteristic of the 
therapeutic mechanism(s), such as intracellular signaling, cytosolic processing, and entry 
into the nucleus, are also important factors governing therapeutic efficacy.  Nonetheless, 
binding mediated by surface receptors is the first step in the delivery pathway, acting as a 
gateway for all subsequent intracellular events.   
Quantitative evaluation methods such as the one employed here can be important 
tools in understanding subcellular events associated with molecular targeting.  However, 
interpretation of any quantitative technique can be complicated by several issues 
involving instrumentation, reagent selection, and methodology-specific factors such as 
antibody/antigen binding valency.  We have taken steps to minimize these difficulties in 
the current study, and have assessed the validity of our results using multiple, redundant 
techniques.  Ultimately, the accuracy of these results depends on immunofluorescence 
methods that are widely accepted and generally applicable for both research and clinical 
understanding. 
A growing body of evidence points to the fundamental role cell surface proteins 
play in determining the physiological activity and experimental response of individual 
cell phenotypes.  This response, in turn, plays a crucial role in governing the 
effectiveness of many specifically targeted gene and drug delivery vectors.  A detailed 
analysis of these surface reactions can be extremely valuable in understanding the 
intracellular process(es) responsible for limiting delivery of active drugs and genes to 
specific cells, as interactions with surface receptors serve as the gateway to these events.  
Quantitative information promises to extend the power and efficacy of current studies by 
allowing a more thorough understanding of the importance of specific cell surface 
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proteins in physiological and disease processes.  This information can then be employed 
in the development of new therapies or the creation of more effective targeting strategies 
for therapies in existence today. 
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3.1 Abstract 
 
Background: Semiconductor nanocrystals such as quantum dots (QDs) are a potentially 
powerful resource in the fields of flow cytometry and fluorescence microscopy.  QD size 
and fluorescence characteristics offer attractive features for use in targeted delivery 
systems and detection by flow cytometry.  While quantitative measurements of a variety 
of fluorescent molecules are routinely performed, fluorophores for which no calibration 
standards exist, such as QDs, pose a problem for quantitation in flow cytometry.  Our 
goal was to develop a targeted nanoparticulate delivery system for therapeutic delivery as 
well as a method to accurately and quantitatively assess the performance of this system. 
 
Methods: We synthesized surface-modified QD probes targeted to cellular surface 
receptors and measured the MFI of the resulting cell-probe conjugates by flow cytometry.  
MFI was converted to mean equivalent R-PE intensity (MEPE) using standard calibration 
microspheres.  Known concentrations of both R-PE and QD probes were measured by 
fluorometry to relate R-PE and QD fluorescence.  Fluorometry results were then used to 
translate MEPE measurements to the number of bound QD probes.   
 
Results: The targeted probes we developed exhibited superior binding characteristics over 
unmodified and untargeted particles.  This binding interaction was shown to be specific 
and mediated by the NGR targeting ligand.  The calibration method developed to assess 
this system proved successful at converting raw fluorescence data to quantitative probe 
binding values. 
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Conclusions: We demonstrate the synthesis and performance of a highly modular 
nanoparticulate system capable of targeted therapeutic delivery and imaging.  The 
calibration method implemented to quantify the performance of this system represents a 
potentially powerful tool to extend truly quantitative measurements to an array of 
fluorescent molecules. 
 
3.2 Introduction 
 Recent advances in library screening and other methods have identified new cell-
specific surface markers potentially suitable for drug and gene delivery.  The NGR 
tripeptide is one such molecule identified as a tumor-homing sequence that selectively 
targets tumor vasculature in vivo (1,2).  Additional studies identified CD13 as the 
receptor for this peptide motif (3).  CD13 expression has been reported in a variety of 
tissues, and a recent study has revealed the existence of at least two distinct isoforms of 
this antigen (4).  Further investigation confirmed that the isoform found in tumorigenic 
cells and angiogenic blood vessels functions as a receptor for the NGR motif, while the 
isoform expressed in normal counterparts of these cells does not appreciably bind NGR 
conjugates.  CD13 overexpression has been measured in both tumor cells and angiogenic 
blood vessels (5,6), providing an appealing and accessible target for directed therapy. 
Molecules targeting receptors such as these have been incorporated into 
liposomes (7-9), microparticles and nanoparticles (10,11), and directly conjugated to 
drugs or genes (2,12,13) to facilitate delivery of high concentrations of therapeutic agents 
to the cell surface.  The use of nanoparticles for this purpose has the inherent advantage 
of a large surface area to volume ratio, allowing conjugation of multiple active 
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molecules.  Stable covalent conjugation of bioactive molecules such as enzymes (14,15), 
mAbs (16), peptides (17), and DNA (18,19) to the surface of NPs has been reported.  
With small-molecule ligands, short peptides, and DNA probes, multiple copies of the 
ligand can be attached to the surface of the QD enabling multivalent binding to target 
cells.   
QDs offer the typical characteristics of other nanoscale objects with the added 
benefit of intense fluorescence characteristics for straightforward and highly sensitive 
detection and imaging.  These attributes impart the ability to integrate detection, imaging, 
and potential treatment characteristics (e.g. therapeutic payload delivery) into a single 
multifunctional nanoparticle.  Particles such as these provide a stable and highly modular 
base for targeted delivery not offered by drugs or imaging materials alone.  Intrinsic 
imaging capability enables detection and performance monitoring of these systems in a 
number of ways – qualitative fluorescence comparisons can be made in real time by 
fluorescence microscopy while more quantitative measurements can be performed by 
techniques such as flow cytometry.  The current generation of QDs has been used 
successfully for both in vitro and small animal in vivo imaging (20,21).  Nanomaterials 
currently in development aim to extend this capability by providing the potential for 
medical imaging with particles such as reduced-toxicity near-infrared (NIR) emitting 
QDs and other nanoparticulate contrast agents. 
Traditional fluorophores (e.g., fluorescein isothiocyanate [FITC], R-phycoerythrin 
[R-PE], and enhanced green fluorescent protein [EGFP]) have been used extensively in 
conjunction with fluorescence microscopy and flow cytometry.  Reliable fluorescence 
calibration standards have enabled users to move beyond basic sample detection and 
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visualization to quantitative measurements utilizing these reagents (22-24).  
Unfortunately, many fluorescent molecules (including QDs) currently lack the necessary 
standards to facilitate quantitative approaches.  Without suitable calibration methods, 
measurements are often limited to qualitative comparisons and relative fluorescence 
intensities (i.e., MFI) with little inherent connection to the biological structure or activity 
under assessment. 
In this report we describe the synthesis and in vitro performance of a QD 
construct capable of multivalent targeted binding to cellular proteins and fluorescent 
labeling of targeted cells.  These data provide a viable modular nanoscale platform 
capable of directed binding and payload delivery to target cells.  Furthermore, we 
illustrate a method for fluorescence calibration of flow cytometry data capable of 
extending quantitative measurement to these molecules as well as to other fluorophores 
for which appropriate calibration standards are not available. 
 
 
3.3 Materials and Methods 
 
 
3.3.1 Cell Culture 
 
HT-1080 cells (human fibrosarcoma, ATCC CCL-121) were maintained and 
subcultured in complete medium containing minimum essential medium (MEM) 
supplemented with 10% fetal bovine serum, 2mM glutamine, 1.5 g/L sodium 
bicarbonate, 0.1mM non-essential amino acids, 1mM sodium pyruvate, and 1% 
antibiotics of penicillin-streptomycin-amphotericin.  All cells were maintained at 37°C, 
5% CO2, and 95% humidity for the duration of the study.  For probe binding assays, cells 
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were grown to confluence in 12-well tissue culture plates (Becton-Dickinson) containing 
1mL/well of supplemented MEM under the conditions described above. 
 
 
3.3.2 Peptides and QD Probes 
 
 The cyclized PEGylated CD13-targeting peptide (HN-PEG-NGR) was 
synthesized and purified by AnaSpec (San Jose, CA), where HN-PEG is a 3400 Da PEG 
chain with functional groups suitable for subsequent synthesis reactions and NGR is the 
cyclized CNGRC targeting peptide.  HN-PEG-NHS is the same PEG chain used in 
synthesis of the PEGylated CD13-targeting peptide described above and was obtained 
from Nektar Therapeutics (Huntsville, AL).  The N-terminal amine group of the desired 
construct was conjugated to the surface of carboxylate QDs (585nm emission; Quantum 
Dot Corp., Hayward, CA) using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC; 
Sigma) to produce QD-PEG and QD-PEG-NGR probes.  Briefly, 250µl of QDs (7.5µM) 
was diluted to 1µM with 10mM borate buffer, pH 7.4.  80µl from a 10mg/ml stock 
solution of HN-PEG-NHS or the HN-PEG-NGR targeting construct was then added to 
the solution.  57µl from a 10mg/ml stock solution of EDC was added and the mixture was 
stirred for 2h at room temperature to complete the conjugation.  A representation of the 
final QD probe conjugates can be seen in Figure 3.1.    
 Following conjugation, the mixture was purified by spin filtration in a 50,000 
nominal molecular weight limit (NMWL) cutoff device (Amicon Ultra-4, Millipore 
Corp.).  Three buffer exchanges were performed with 50mM borate buffer (pH 8.3) and 
the final conjugate was stored at 4ºC.  The concentration of the final purified product was  
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Figure 3.1. The capacity for cell binding of three distinct QD probes is characterized in this study.  
Representative structures of these probes are shown here.  Unmodified QDs (left) consist of a 
semiconductor CdSe base (red) coated with an amphiphilic (AMP) polymer (green).  QD-PEG probes (top 
right) are synthesized by modifying AMP QDs with multiple copies of PEG3400 polymer (black).  QD-PEG-
NGR probes (bottom right) are similar to QD-PEG probes with the addition of a distal NGR targeting 
peptide (blue).  The conjugation of many identical PEG-NGR ligands enables multivalent interaction of the 
QD probes with targets on the cell surface. 
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determined by measuring the absorbance at 575nm using a QD extinction coefficient of 
400,000M-1cm-1.  As this value is a characteristic of the semiconductor core, the 
extinction coefficient is presumably unchanged by surface functionalization.  However, 
conjugation of molecules to the QD surface does have an effect on the fluorescence 
emission (i.e. quantum yield) of the final construct.  
 
3.3.3 QD Probe Binding to Cellular Targets in vitro 
Ligand-target cell interactions were conducted in an in vitro cell culture model.  
Target HT-1080 cell samples were grown to confluence in 12-well tissue culture plates 
prior to biological experimentation.  QD-PEG-NGR solutions (50 or 100nM) in 
OptiMEM supplemented with 1% BSA were introduced and incubated with cell samples 
for 1hr at 37ºC on a shaker plate to promote convective transport of the targeted probes.   
Blocking studies followed the same protocol, with the addition of a 10-fold excess of 
soluble NGR added to the QD-PEG-NGR solution.   
 Following incubation and probe binding, QD solutions were aspirated and cell 
monolayers were washed three times with fresh PBS to remove any unbound QD probes.  
QD binding to adherent cells was then documented by fluorescence microscopy.  Culture 
wells were treated with a nonenzymatic cell dissociation solution (Sigma) to detach the 
cell monolayer from the surface.  The resulting samples were centrifuged for 5min at 
900×g, resuspended in 500µl of fresh PBS, filtered through a 70mm mesh, and 
immediately analyzed by flow cytometry.   
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3.3.4 Photomicroscopy 
 
 The fluorescence of adherent HT-1080 cells following incubation with QD probes 
was documented by fluorescence microscopy.  After washing the cell monolayer surface, 
phase contrast and corresponding fluorescence photomicrographs were taken of each 
experimental well.  Samples were analyzed on a Nikon TE2000U inverted microscope 
using a fluorescence filter cube specifically designed for 585nm emission QDs (Chroma 
Technology).  Images were obtained with a Hamamatsu C7780 3 channel CCD cooled 
digital camera driven with Image-Pro Plus software (Media Cybernetics) and saved as 
individual JPEG files.  Each experimental well was imaged at 10x magnification.   
 
 
3.3.5 Quantification of QD Probe Binding 
 
Flow Cytometry.  Fluorescence of all samples was measured on a FACSCalibur flow 
cytometer (Becton-Dickinson).  CellQuest software (Becton-Dickinson) was used for all 
data acquisition.  Cell-associated QD probe fluorescence as well as R-PE calibration 
microsphere emission was measured in the FL2 channel (band pass filter 585/42 nm).  
Data on forward scatter was collected in linear mode while all other parameters were 
collected in log mode.  Twenty thousand events were collected by list-mode data for all 
samples, and the mean intensity (MFI) from the histograms for each sample was used to 
analyze their fluorescence intensity.  WinList software (Verity Software House) was used 
to further prepare and analyze the list-mode data following collection. 
For data acquisition, the cell region was determined by utilizing FSC and SSC 
measurements.  Samples were then analyzed and the MFI of the FL2 channel was 
recorded for each sample.  HT-1080 autofluorescence (from cells untreated with QD 
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probes) was subtracted from these fluorescence intensities to arrive at a final 
measurement for further analysis.  Quantum™ PE MESF microspheres (Bangs Labs) 
were analyzed by flow cytometry under the same conditions and settings used in 
biological experimentation.     
 
Fluorometry.  Fluorescence spectra of both QD probes and soluble R-PE were measured 
on an LS 50 B luminescence spectrometer (Perkin Elmer).  For R-PE, 1667, 833.5, 250, 
166.7 and 16.67nM concentrations as well as blank PBS were measured in a small-
volume quartz cuvette.  Samples were excited at 488nm (5nm slit) and emission profiles 
were recorded from 564-606nm (5nm slit).  Emission intensities for each sample were 
integrated to determine the total intensity within the measurement range (integrated 
intensity).  A standard curve was then prepared relating R-PE concentration to measured 
integrated fluorescence intensity.  QD probe fluorescence was measured using the same 
settings and the integrated intensity of these samples was compared to the standard curve 
to determine the equivalent number of R-PE molecules (i.e. the number of R-PE 
molecules required to equal the fluorescence of a QD probe). 
 
Cross-correlation.  R-PE calibration microspheres were used to correlate fluorescence 
measurements on the flow cytometer to R-PE, producing a standard curve relating 
measured MFI to the number of equivalent R-PE molecules.  A standard curve of 
calculated integrated intensities from fluorometry was used to determine the number of 
R-PE molecules per QD probe.  Using this comparison, a new standard curve was 
produced relating MFI measured by flow cytometry to the number of QD probes.  This 
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standard curve allows direct conversion of fluorescence measured by flow cytometry to 
the number of bound QD probes per cell in biological assays. 
 
 
3.4 Results 
 
3.4.1 Surface modification of QD probes 
 The surface of AMP QDs was successfully modified with the NGR targeting 
ligand.  We characterized the electrophoretic mobility of our QD probes to determine the 
success of the surface modification reaction.  Figure 3.2 shows the difference in mobility 
between AMP QDs and those modified with the NGR ligand.  Conjugation of multiple 
targeting ligands to the QD surface results in a significant increase in molecular weight 
(MW) of the probe and a corresponding decrease in electrophoretic mobility.   
 
 
3.4.2 Probe binding to target cells 
 Biologically active cell-targeting peptides retain the capacity for specific binding 
to target cells after attachment to the QD surface.  We tested the binding of QD-PEG-
NGR conjugates to HT-1080 cells expressing high levels of the target CD13 receptor 
(Figure 3.3).  Fluorescence photomicrographs revealed significant QD binding to target 
cells when the NGR targeting ligand was attached to the surface (Figure 3.4A, B).  This 
interaction is nearly completely inhibited by competitive binding with excess soluble 
NGR ligand (Figure 3.4C, D).  These photos give a qualitative view of QD probe 
binding, but do not yield quantitative results. 
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Figure 3.2. The surface of AMP QDs was successfully modified with the PEG-NGR targeting ligand.  
Electrophoretic mobility of QDs was assessed on a 1% agarose gel.  Gels were run in 1X TAE buffer under 
a voltage of 150mV.  Mobility of QDs exhibiting the PEG-NGR ligand (right lane) is reduced compared to 
that of unmodified AMP QDs (left lane), suggesting successful modification of the QD surface.  The 
conjugation of multiple ligands to the QD surface increases the MW of the construct, resulting in reduced 
electrophoretic mobility.  This image is representative of three independent measurements. 
QD motion 
 71
FL2 Intensity
1 10 100 1000 10000
N
um
be
r
0
1000
2000
3000
4000
5000
6000
Control HT-1080
HT-1080 + anti-CD13/R-PE
 
 
 
Figure 3.3. HT-1080 cells express high levels of the CD13 protein on their surface.  Control, untreated HT-
1080 cells generate low autofluorescence in the FL2 wavelength range when measured by flow cytometry.  
Incubation of the cells with an R-PE labeled anti-CD13 mAb (anti-CD13/R-PE) produces a unimodal cell 
population with an average FL2 intensity more than 1000-fold greater than that of untreated HT-1080 cells, 
presumably correlated with high expression levels of the CD13 antigen on the cell surface.
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Figure 3.4. NGR surface functionalization specifically mediates QD binding to HT-1080 cells.  Cells were 
grown to confluence in 12-well culture plates and incubated with a 50nM QD probe solution for 1h.  
Images are representative of n ≥ 3 for all experimental cohorts.  B. QDs functionalized with the NGR 
peptide interact extensively with the HT-1080 cell surface, resulting in a relatively high level of visible QD 
fluorescence in this photomicrograph.  D. Addition of 10-fold excess NGR ligand concurrently with QD-
NGR inhibited nearly all QD interaction with the cell surface, greatly reducing detectable fluorescence.  A, 
C. Phase contrast images of cultured cells.   
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Flow cytometry confirms the trends observed in the photomicrographs for these 
studies and yields data for quantitative analysis of binding interaction (Figure 3.5).  A 
distinct shift in cellular FL2 fluorescence was measured after incubation with QD-PEG-
NGR probes, indicating a strong interaction of the probe with the cellular surface.  
Control HT-1080 cells had a mean FL2 of 2.7 a.u. while those treated with the targeted 
QD probes had a mean intensity of 101.5 a.u.  This shift in fluorescence intensity 
suggests significant interaction of the probes with the cell surface, which can be further 
quantified by the calibration method described in this work. 
Surface modification greatly influences QD association with the cell surface.  We 
tested the binding of three 50nM solutions of QD probes (unmodified AMP QDs, QD-
PEG, and QD-PEG-NGR) to HT-1080 cells expressing high levels of the target CD13 
receptor.  Flow cytometry revealed markedly different interactions among each of these 
cohorts (Figure 3.5).  HT-1080 cells had a mean intensity of 95.9 a.u. after incubation 
with AMP QDs, revealing considerable interaction of the amphiphilic polymer coating 
with the cell surface.  This intensity fell to 3.6 a.u. (a 96% reduction) when the surface of 
the QDs was modified with PEG, demonstrating the ability of the PEG coating to mask 
recognition of the amphiphilic polymer.   
The specificity of QD-PEG-NGR probe binding was further tested by competition 
with free NGR peptide.  Introduction of a 10-fold excess of this ligand reduced the mean 
FL2 intensity from 101.5 to 11.5 a.u., an 89% reduction in probe binding to the cell 
surface.  Addition of soluble BSA, however, had no effect on QD binding (data not 
shown).  These results suggest that QD-PEG-NGR probe binding is modulated primarily 
through specific binding of the NGR peptide to antigens on the cell surface.
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Figure 3.5. Surface modification influences QD probe interaction with cultured target HT-1080 cells as 
detected by changes in fluorescence intensity measured by flow cytometry.  Cells were grown to 
confluence in 12-well culture plates and incubated for 1h with a 50nM QD probe solution.  Control HT-
1080 cells prior to incubation with QDs (black) exhibit low-level autofluorescence.  QDs presenting the 
native AMP coating (green) are significantly associated with HT-1080 cells.  The mechanism of 
unmodified QD association with cells is non-ligand mediated based on the binding inhibition provided by 
PEG modification of the QD surface (blue).  Addition of the NGR targeting ligand to the QD-PEG, 
producing the QD-PEG-NGR construct (solid red), regenerates extensive interaction with the cell surface.  
Nearly all of the NGR-mediated interaction can be blocked by coincubation of the cells with a 10-fold 
excess of free NGR ligand (dashed red), providing evidence for specificity of QD-PEG-NGR interaction 
with cells.  A quantitative analysis of these flow cytometric histograms appears in Figure 7.  20,000 cells 
were recorded during each trial.  Histograms are representative of n ≥ 3 for all experimental cohorts.  
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3.4.3 Calibration of fluorescence data 
 
 A linear relationship exists between QD concentration and fluorescence intensity.    
To perform QD binding quantitation, fluorescence measurements were made by both 
fluorometry and flow cytometry.  Integrated intensities (564-606nm) of both soluble R- 
PE and QDs were measured by fluorometry (Table 3.1).  Data was then used to generate 
standard curves for these molecules relating integrated intensity to molecule 
concentration (Fig 3.6A).  The linear regression equations were then set equal to one 
another, producing a standard curve that directly relates AMP QD and R-PE 
concentrations (Equation 3.1). 
 
(3.1)  [ ] [ ] 1005.122638.0PEQD −×=  
 
 Fluorescence measurements made by flow cytometry were then calibrated to the 
number of equivalent R-PE molecules using standard calibration microspheres (Figure 
3.6B).  This standard curve was then combined with the fluorometry results to produce a 
new relationship capable of directly correlating FL2 intensity measured by flow 
cytometry to the number of equivalent bound AMP QDs (Equation 3.2).  To obtain 
quantitative binding values for both QD-PEG and QD-PEG-NGR probes, the calculated 
number of AMP QDs was factored by their measured relative fluorescence to AMP QDs 
(Table 3.1). 
 
(3.2)  1005.122638.0)8.163972.4382([QD] −×+×= FL  
The particular relationships developed here are valid only for the particular 
system of fluorophores (AMP QD and R-PE), flow cytometer, and settings used in this  
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Integrated Fluorescence 
Intensity 
Relative Brightness 
(compared to AMP QD) 
500nM AMP QD 36547.6 1 
250nM AMP QD 21230.1 1 
125nM AMP QD 10407.3 1 
75nM AMP QD 9207.7 1 
62.5nM AMP QD 3725.7 1 
1667nM R-PE 32568.0 0.24 
833.5nM R-PE 15693.6 0.24 
250nM R-PE 3731.5 0.24 
166.7nM R-PE 3554.6 0.24 
16.7nM R-PE 195.4 0.24 
600nM QD-PEG-NGR 35689.9 0.77 
350nM QD-PEG 11457.4 0.43 
 
Table 3.1. Integrated intensities of QD probes and R-PE were measured by fluorometry to produce 
calibration standard curves (Figure 3.6) for quantitative analysis.  Curves for AMP QD and R-PE were then 
compared to develop a direct relationship correlating the numbers of AMP QD and R-PE molecules 
(Equation 3.1).  Fluorescence settings were chosen to match the spectral excitation and emission 
characteristics of the FACSCalibur flow cytometer used in this study.  These measurements confirm that 
QD fluorescence intensity is large relative to traditional fluorophores.  Furthermore, these measurements 
reveal that surface modification of native AMP QDs significantly modulates fluorescence emission 
intensity of the QD probes.  This modification can be compensated for by the calibration method described 
here. 
 77
Composite Fluorescence (a.u.)
0 10000 20000 30000 40000
C
on
ce
nt
ra
tio
n 
(n
M
)
0
200
400
600
800
1000
1200
1400
1600
1800
AMP QD
R-PE
 A. 
 
 
 
 
 
 
 
 
 
 
 
 
FL2 Intensity (a.u.)
0 200 400 600 800
M
EP
E
0.0
5.0e+4
1.0e+5
1.5e+5
2.0e+5
2.5e+5
3.0e+5
3.5e+5
B. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6. Indirect calibration must be performed to quantitatively analyze fluorophores for which no 
standards are available.  A. Fluorometry measurements were used to develop standard curves illustrating 
measured fluorescence as a function of QD or R-PE concentration.  These standard curves can be used to 
determine the relationship between R-PE and QD fluorescence intensity.  B. Flow cytometry fluorescence 
intensity measurements were translated to the number of equivalent soluble R-PE molecules (MEPE) using 
commercially available calibration microspheres.  Fluorometry and flow cytometry measurements were 
then combined to develop a direct relationship between flow cytometry fluorescence intensity and the 
number of equivalent QD probes. 
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calibration.  In particular, measurements were conducted on the other two QD species 
used in this study (QD-PEG and QD-PEG-NGR) as the surface treatments modulated the 
QD fluorescence quantum yield.  This modulated fluorescence behavior essentially 
created three unique ‘orphan’ fluorophores and resulted in three unique quantitative 
correlation relationships with the R-PE standards.  The results, quantitative assessment of 
the number of QDs associated with each cellular event, are absolute values that can be 
directly compared among the three QD cohorts.  The QD per cell results, but not the raw 
fluorescence intensities, can also be compared to quantitative results from other 
instruments, settings and reagents. 
 
3.4.4 Quantitative measurement of QD probe binding to cells in vitro 
 
 Flow cytometry results, coupled with fluorometer-flow cytometer cross 
calibration, can be used to determine the number of QD probes bound to the cell surface.  
The standard curve obtained from the fluorometer-flow cytometer cross calibration was 
used to relate the measured FL2 intensity shift of cellular samples to the corresponding 
number of bound QD probes.  The results for each QD surface coating are shown in 
Figure 3.7A.  AMP QDs exhibited significant binding of 11,010 ± 490/cell to the surface 
of HT-1080 cells.  Modification of the QD surface with PEG significantly reduced this 
interaction to 1090 ± 60/cell.  Addition of the NGR targeting peptide produced the 
highest cellular interaction of 15410 ± 980/cell, while introduction of competitive binding 
with 10-fold excess NGR peptide blocked 88% of binding to 1870 ± 50/cell.  Similar 
results were seen in experiments utilizing 100nM QD probes (Figure 3.7B). 
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The interaction of 50nM QD probes with HT-1080 cells was measured.  Unmodified AMP QDs exhibit a 
high level of binding  (11014 ± 493 QD/cell) that can be overcome by surface modification with PEG 
(1094 ± 64 QD/cell).  Addition of the NGR targeting ligand to QD-PEG-NGR results in extensive probe 
binding to the cell surface (15406 ± 980 QD/cell,).  Nearly 90% of this NGR-mediated binding can be 
inhibited with the addition of a 10-fold excess of free NGR ligand (1867 ± 51 QD/cell).  B. Increasing 
probe concentration results in higher levels of QD probe binding.  QD-PEG-NGR probe binding nearly 
doubled to 28987 ± 602/cell with increased QD concentration.  Minor increases in binding were measur
at the increased concentration with QD-PEG (1182 ± 58 QD/cell) and QD-PEG-NGR inhibited with free
NGR (2390 ± 39 QD/cell).  n ≥ 3 for all experimental cohorts.  Bar height is the mean and error bars reflect
standard deviation (standard deviation is too low to visualize error bars for QD-PEG-NGR + free NGR and
QD-PEG samples on this scale).  
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The interaction of 50nM QD probes with HT-1080 cells was measured.  Unmodified AMP QDs exhibit a 
high level of binding  (11014 ± 493 QD/cell) that can be overcome by surface modification with PEG 
(1094 ± 64 QD/cell).  Addition of the NGR targeting ligand to QD-PEG-NGR results in extensive probe 
binding to the cell surface (15406 ± 980 QD/cell,).  Nearly 90% of this NGR-mediated binding can be 
inhibited with the addition of a 10-fold excess of free NGR ligand (1867 ± 51 QD/cell).  B. Increasing 
probe concentration results in higher levels of QD probe binding.  QD-PEG-NGR probe binding nearly 
doubled to 28987 ± 602/cell with increased QD concentration.  Minor increases in binding were measur
at the increased concentration with QD-PEG (1182 ± 58 QD/cell) and QD-PEG-NGR inhibited with free
NGR (2390 ± 39 QD/cell).  n ≥ 3 for all experimental cohorts.  Bar height is the mean and error bars reflect
standard deviation (standard deviation is too low to visualize error bars for QD-PEG-NGR + free NGR and
QD-PEG samples on this scale).  
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3.5 Discussion 
 
 Traditional approaches to disease treatment often involve systemic doses of 
highly toxic drugs.  These approaches are typically limited by nonspecific delivery to 
non-target cells, resulting systemic toxicity (25).  Similarly, many imaging reagents are 
delivered in bolus systemic doses, effectively reducing overall detection sensitivity (by 
increasing background) or limiting their application to easily accessible compartments 
(e.g. vasculature).  Many prior efforts have focused on targeted delivery of drugs, genes, 
or imaging agents directly to the target cell type(s) both in vitro (26-28) and in vivo (29-
31).  However, while offering improvements over nondiscriminant systemic therapies 
many of these approaches suffer from either suboptimal targeting or only a partial 
quantitative (or even qualitative) analysis of interaction with target sites.   
The current study expands on these previous efforts by demonstration of the 
synthesis and in vitro performance of a versatile, modular nanoscale platform capable of 
targeted binding, sensing of biological events, and labeling of target cells.  Furthermore, 
we describe a general method for calibration of flow cytometry fluorescence data capable 
of providing truly quantitative measurements of these constructs and other fluorophores 
for which appropriate calibration standards are not currently available.  This method is 
implemented here to determine the number of QDs associated with cells in vitro as a 
function of surface characteristics. 
 Nanoparticulate systems offer a versatile platform with several distinct 
advantages in the realm of in vitro and in vivo targeted delivery and detection.  Physical 
characteristics of the nanoparticle base impart features not available with molecular 
structures alone.  These systems provide the opportunity for colocalization of molecular 
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species and the potential for multifunctional capability.  Benefits such as these are limited 
in the absence of a particle, as molecular structures offer lower valency for 
functionalization and increased likelihood of functional changes following modification.  
Surface chemistry and three-dimensional particulate structure enable the use of NP 
systems to provide targeted or localized delivery, to improve bioavailability, to sustain 
the delivered effect in target tissues, to solubilize agents for intravascular delivery, to 
improve the stability of therapeutic agents against enzymatic degradation and clearance, 
and to allow manipulation of the release profile of the delivered therapeutic agent (32).  
Due to their small physical size, nanoparticles can also penetrate deep into tissues, 
through fine capillaries, and are generally incorporated efficiently by cells (33).  
QDs offer all of the advantages of NP delivery systems previously described with 
the added benefit of an intrinsic imaging component.  The intense fluorescence 
characteristics of QD probes relative to organic fluorophores facilitates sensitive 
detection of cell surface interaction not possible with traditional approaches.  Qualitative 
fluorescence comparisons can be made by fluorescence microscopy while more 
quantitative measurements can be performed by techniques such as flow cytometry.  
Furthermore, the spectral characteristics of QD fluorescence lend themselves to the 
possibility of multiplexed detection of targets.  Multiple colors of QD probes can be 
excited using a single light source while narrow emission bands enable simultaneous 
detection of multiple different QD colors (corresponding to multiple targets) with 
minimal crosstalk between detection channels. 
Enhanced delivery and distribution of nanoscale structures to the desired cell 
population(s) can be achieved by both passive and active targeting principles.  A common 
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approach to passive targeting, as utilized in this study, uses chemical modification, often 
applying PEG polymers directly onto the drug or delivery device (34-36).  Passive 
targeting also refers to the preferential, size-based extravasation of nanomaterials through 
the relatively porous vasculature of many tumors.  The small physical diameter of the QD 
nanoprobes utilized in this study allows them to retain many transport characteristics of 
molecular structures.  Thus, these constructs have access to fine capillaries, are capable of 
extravasation, and can penetrate deep into tissues through size restrictive structures 
(34,37). 
 Active targeting is achieved by increasing the affinity of the delivery system for 
the target site(s).  This is often accomplished by the introduction of ligands such as 
monoclonal antibodies (mAbs) or peptides (as in the current study) for specific 
recognition of a particular protein or cellular receptor.  The effectiveness of some specific 
targeting ligands has been documented and incorporated into a handful of commercially 
available treatments (e.g. Glivec®, Herceptin®, Iressa).  Thus, chemical modification of 
drugs or delivery devices can have a significant impact on affinity for both target and 
non-target sites.   
 
Probe Binding 
 
 Our QD probe targeting studies conducted by flow cytometry (Figures 3.4, 3.5) 
confirm the dependence of nanoparticle surface modification on cell surface target 
interaction.  PEGylation of the QD surface resulted in a significant decrease in binding 
over unmodified AMP QDs, with a nearly 90% reduction in nonspecific interaction.  This 
is consistent with previous reports (34-36) detailing the ability of PEG polymers to 
passivate the surface and minimize undesired interactions with non-target sites.  
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PEGylated QDs serve as the control for specific binding experiments, as targeted probes 
are built from the same platform with an added NGR ligand on the distal end of the PEG.  
Addition of this peptide ligand to the PEG coating mediated a substantial increase in QD 
binding to the cell surface.  Interactions between HT-1080 cells and QD-PEG-NGR 
increased by 1300% over PEGylated QDs and 40% over unmodified AMP QDs, 
suggesting significant specific recognition of the NGR targeting ligand by molecules on 
the cellular surface.  These results also follow expected trends for traditional ligand-
receptor interaction.  Although no specific Km value is available to describe NGR/CD13 
binding, QD-NGR concentrations used in binding experiments are well below values 
reported for other peptide-receptor pairs.  Thus, QD-NGR binding is expected to be a 
function of QD-NGR concentration.  This behavior is apparent when comparing results 
for 50nM and 100nM QD-NGR binding. 
Competitive binding experiments were conducted to further examine the 
specificity of targeted QD probe binding.  The addition of a 10-fold excess of free NGR 
ligand resulted in an 88% inhibition of targeted probe binding (100nM experiments saw a 
92% reduction), thus actively reducing binding to levels approaching those of simple 
PEGylated QDs.  Furthermore, the addition of 1% BSA during the binding assay had no 
effect on QD probe binding (data not shown), additional evidence that targeted probe 
interactions are not mediated by nonspecific interactions.  These experimental results 
strongly suggest that increased targeted QD probe binding is a direct result of 
modification with the NGR targeting ligand, and that this binding is mediated by specific 
interactions of the NGR ligand with molecules on the cell surface.   
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While fluorescence shifts measured by flow cytometry indicate functional QD 
binding to the cell surface and enable “quantitative” comparisons and relative binding 
levels, they are not a direct quantitative measure of the number of probes present on the 
cell surface.  Fluorescence intensity is modulated by multiple factors, ranging from the 
particular fluorophore used to specific instrument settings in use.  Thus, direct 
comparisons of raw fluorescence data are not necessarily accurate indicators of the 
number of bound probes, especially across multiple systems, instruments and reagents.  
To ensure portability and reproducibility, FACS fluorescence intensity data must be 
correlated to physical values unaffected by experimental conditions. 
 
Calibration 
 
Photomicrographs (Figure 3.5) illustrate considerable modulation of QD probe 
binding by surface treatment modification.  Photomicrographs support qualitative 
assessments, but are difficult to interpret in terms of fluorescence intensity per cell.  
Fluorescence intensities measured by flow cytometry have been employed in a number of 
studies, including the current work, to measure the effects of both passive and active 
targeting mechanisms (38-40).  These approaches provide considerably more information 
for interpretation and enable simple quantitative comparisons.  Nevertheless, 
fluorescence intensity measurements alone do not support quantitative analysis of probe 
binding due to a lack of calibration between probe number and fluorescence intensity. 
 Methods to provide calibrated fluorescence intensities for flow cytometry are 
limited by the availability of appropriate standards.  In many cases, such as with QDs, no 
commercially available standards currently exist to provide reliable calibrations (‘orphan’ 
fluorophores).  In these instances, alternative methods must be developed to allow 
 86
indirect calibration of measured fluorescence data.  The calibrated flow cytometry 
methods utilized here are a principal component in this work.   
A similar approach was previously used to analyze fluorophores for which 
commercial calibration standards were not available (41).  This technique is based on 
comparison of the fluorescence (as measured by fluorometry) of the ‘orphan’ fluorophore 
(QDs) to that of a fluorophore with available calibration standards (R-PE).  The resulting 
relationship between concentration of the two fluorophores and the measured 
fluorescence intensities can be presented as a type of calibration curve that, in this case, is 
linear (Figure 3.6A).  This relationship can be used to make a direct comparison between 
AMP QD and R-PE concentration (Equation 3.1).   
Accurate calibration of ‘orphan’ fluorophores by flow cytometry requires 
fluorometry measurements using excitation and emission settings that mimic the 
fluorescence characteristics of the flow cytometer.  For example, the FACSCalibur used 
in our studies utilizes a single excitation laser (488nm) while the R-PE and QD 
fluorophores are maximally detected in the FL2 channel (585/42nm).  Fluorometer 
settings were chosen to closely match these characteristics.  Excitation was set to 488nm 
(5nm slit) while the emission intensities were measured from 564-606nm.  Performing 
these measurements under the same conditions (e.g. pH, buffer components, etc.) 
minimizes the introduction of error due to environmental modulation of fluorescence. 
Another potentially important factor is spectral matching in the choice of 
fluorescent markers.  Ideally, the chosen fluorophores are sufficiently excited by the same 
laser line and detected by flow cytometry using the same fluorescence channel.   This 
insures sufficient sensitivity for both fluorometry and flow cytometry measurements and 
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minimizes error due to spectral mismatch.  An additional factor affecting fluorophore 
selection includes quenching, which may be an issue at high concentrations.  In our case 
R-PE was chosen as the calibration fluorophore, as it is very bright and exhibits minimal 
self-quenching (42). Although R-PE is exceedingly resistant to self-quenching, the 
behavior of other fluorophores must be carefully considered when choosing a compatible 
marker to achieve quantitative results. 
Translation of the fluorescence cross-calibration in Figure 3.6A to quantitative 
interpretation of flow cytometry data requires a calibrated scale for fluorescence intensity 
of one fluorophore.  Such a calibration is routinely conducted using commercially 
available reagents (43,44) and appears here as Figure 3.6B for R-PE.  Combining this 
calculated standard curve with the previously calculated QD to R-PE comparison 
provides a means for direct conversion of MFI to the number of bound QD probes 
(Equation 3.2).         
By applying the calculated calibration equation (Equation 3.2) we were able to 
translate fluorescence intensity values into meaningful measurements of bound QD 
probes/cell.  For targeted therapy or imaging studies, quantitative values such as these 
can provide important information such as probe binding efficiency, cellular 
susceptibility to targeted therapy, or expected therapy payload delivery – measurements 
not possible with traditional uncalibrated flow cytometry techniques.  These values are 
also especially significant for imaging and detection applications, as contrast 
enhancement and labeling intensity are a direct function of the number of delivered 
contrast agents.  Furthermore, these calibrated values provide a valuable real-world 
translation of arbitrary fluorescence values, enabling greater understanding and data 
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portability among instruments.  It is possible that some QDs were removed from the cell 
surface during cell dissociation, resulting in an artificially low measurement of QD/cell.  
Thus, the values reported here serve as a lower bound for QD/cell.  Any removal of QDs 
from the cell surface during the cell dissociation protocol would only serve to increase 
the effectiveness of QD-NGR conjugates synthesized in this work. 
This technique unlocks the underlying power of flow cytometry to allow more 
detailed quantitative evaluations of probe binding as well as the ability to provide more 
detailed information on kinetics and efficiency not possible with traditional techniques.  
For example, measurements from traditional FACS analysis can yield only arbitrary 
fluorescence increases over time.  A conversion to quantitative analysis enables these 
measurements to provide kinetic probe binding values revealing the number of probes 
bound per time, data which are especially useful for targeted delivery and dosage studies.  
Additional analysis can also be performed on the data provided in this study.  
Fractional binding (total QD added/total QD bound) is nearly identical between 50nM 
and 100nM samples (0.20% and 0.19%, respectively).  These very low values suggest 
that probe binding has not yet reached saturation at these concentrations and is limited by 
factors other than QD surface modification.  Access to the cell surface is one probable 
cause, as the colloidal QD probes do not settle during incubation.  Furthermore, 
incubation time (1h) is sufficiently short to limit significant passive motion of the 
nanoprobes to the cell surface. 
Data on additional probe concentrations and incubation times would enable access 
to a range of supplementary quantitative characteristics including binding constants, 
kinetics of saturation, and the number of nanoprobe binding sites, among others.  These 
 89
examples highlight the importance of quantitative data conversion to further analysis of 
existing FACS measurements.  These evaluations have the ability to provide valuable 
detailed information not accessible with raw fluorescence data.   
Conclusions 
 
 We describe the development and performance of a nanoparticle system capable 
of targeted binding and delivery, along with a method for providing quantitative 
performance analysis of this system and a range of other fluorescent molecules.  This 
system offers several distinct advantages over traditional molecular delivery techniques 
to increase therapeutic efficiency and efficacy while offering a powerful imaging 
component, especially for in vitro analysis.  The calibration method developed and 
employed in this work allows a straightforward conversion of relative fluorescence 
values into meaningful measurements not affected by experimental conditions.  This 
method extends the capability of quantitative flow cytometry measurements to include 
fluorescent molecules (e.g. QDs) and fluorophores for which no reliable calibration 
standards currently exist. 
 
 
 
 90
3.6 References 
1. Pasqualini R, Koivunen E, Ruoslahti E. Alpha v integrins as receptors for tumor 
targeting by circulating ligands. Nat Biotechnol 1997;15(6):542-6. 
 
2. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to 
tumor vasculature in a mouse model. Science 1998;279(5349):377-80. 
 
3. Pasqualini R, Koivunen E, Kain R, Lahdenranta J, Sakamoto M, Stryhn A, 
Ashmun RA, Shapiro LH, Arap W, Ruoslahti E. Aminopeptidase N is a receptor 
for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res 
2000;60(3):722-7. 
 
4. Curnis F, Arrigoni G, Sacchi A, Fischetti L, Arap W, Pasqualini R, Corti A. 
Differential binding of drugs containing the NGR motif to CD13 isoforms in 
tumor vessels, epithelia, and myeloid cells. Cancer Res 2002;62(3):867-74. 
 
5. van Hensbergen Y, Broxterman HJ, Hanemaaijer R, Jorna AS, van Lent NA, 
Verheul HM, Pinedo HM, Hoekman K. Soluble aminopeptidase N/CD13 in 
malignant and nonmalignant effusions and intratumoral fluid. Clin Cancer Res 
2002;8(12):3747-54. 
 
6. van Hensbergen Y, Broxterman HJ, Rana S, van Diest PJ, Duyndam MC, 
Hoekman K, Pinedo HM, Boven E. Reduced growth, increased vascular area, and 
reduced response to cisplatin in CD13-overexpressing human ovarian cancer 
xenografts. Clin Cancer Res 2004;10(3):1180-91. 
 
7. Oku N, Asai T, Watanabe K, Kuromi K, Ogino K, Taki T. Anti-neovascular 
therapy by use of liposomes targeted to angiogenic vessels. J Liposome Res 
2003;13(1):25-7. 
 
8. Hallahan D, Geng L, Qu S, Scarfone C, Giorgio T, Donnelly E, Gao X, Clanton J. 
Integrin-mediated targeting of drug delivery to irradiated tumor blood vessels. 
Cancer Cell 2003;3(1):63-74. 
 
9. Mamot C, Drummond DC, Greiser U, Hong K, Kirpotin DB, Marks JD, Park JW. 
Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate 
specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing 
tumor cells. Cancer Res 2003;63(12):3154-61. 
 
10. Chenevier P, Delord B, Amedee J, Bareille R, Ichas F, Roux D. RGD-
functionalized spherulites as targeted vectors captured by adherent cultured cells. 
Biochim Biophys Acta 2002;1593(1):17-27. 
 
 91
11. Hood JD, Bednarski M, Frausto R, Guccione S, Reisfeld RA, Xiang R, Cheresh 
DA. Tumor regression by targeted gene delivery to the neovasculature. Science 
2002;296(5577):2404-7. 
 
12. Harbottle RP, Cooper RG, Hart SL, Ladhoff A, McKay T, Knight AM, Wagner E, 
Miller AD, Coutelle C. An RGD-oligolysine peptide: a prototype construct for 
integrin-mediated gene delivery. Hum Gene Ther 1998;9(7):1037-47. 
 
13. Hart SL, Collins L, Gustafsson K, Fabre JW. Integrin-mediated transfection with 
peptides containing arginine-glycine-aspartic acid domains. Gene Ther 
1997;4(11):1225-30. 
 
14. Phadtare S, Vinod VP, Mukhopadhyay K, Kumar A, Rao M, Chaudhari RV, 
Sastry M. Immobilization and biocatalytic activity of fungal protease on gold 
nanoparticle-loaded zeolite microspheres. Biotechnol Bioeng 2004;85(6):629-37. 
 
15. Rossi LM, Quach AD, Rosenzweig Z. Glucose oxidase-magnetite nanoparticle 
bioconjugate for glucose sensing. Anal Bioanal Chem 2004;380(4):606-13. 
 
16. Tang DP, Yuan R, Chai YQ, Zhong X, Liu Y, Dai JY, Zhang LY. Novel 
potentiometric immunosensor for hepatitis B surface antigen using a gold 
nanoparticle-based biomolecular immobilization method. Anal Biochem 
2004;333(2):345-50. 
 
17. Liu J, Zhang Q, Remsen EE, Wooley KL. Nanostructured materials designed for 
cell binding and transduction. Biomacromolecules 2001;2(2):362-8. 
 
18. Zhang D, Chen Y, Chen HY, Xia XH. Silica-nanoparticle-based interface for the 
enhanced immobilization and sequence-specific detection of DNA. Anal Bioanal 
Chem 2004;379(7-8):1025-30. 
 
19. Wang M, Sun C, Wang L, Ji X, Bai Y, Li T, Li J. Electrochemical detection of 
DNA immobilized on gold colloid particles modified self-assembled monolayer 
electrode with silver nanoparticle label. J Pharm Biomed Anal 2003;33(5):1117-
25. 
 
20. Medintz IL, Uyeda HT, Goldman ER, Mattoussi H. Quantum dot bioconjugates 
for imaging, labelling and sensing. Nat Mater 2005;4(6):435-46. 
 
21. Alivisatos AP, Gu W, Larabell C. Quantum dots as cellular probes. Annu Rev 
Biomed Eng 2005;7:55-76. 
 
22. Gerena-Lopez Y, Nolan J, Wang L, Gaigalas A, Schwartz A, Fernandez-Repollet 
E. Quantification of EGFP expression on Molt-4 T cells using calibration 
standards. Cytometry A 2004;60(1):21-8. 
 92
23. Schwartz A, Fernandez-Repollet E. Quantitative flow cytometry. Clin Lab Med 
2001;21(4):743-61. 
 
24. Smith RA, Giorgio TD. Quantitation and kinetics of CD51 surface receptor 
expression: implications for targeted delivery. Ann Biomed Eng 2004;32(5):635-
44. 
 
25. Frei E. Combination chemotherapy, dose and schedule. Cancer Medicine; 1997. p 
817-837. 
 
26. Colin M, Maurice M, Trugnan G, Kornprobst M, Harbottle RP, Knight A, Cooper 
RG, Miller AD, Capeau J, Coutelle C and others. Cell delivery, intracellular 
trafficking and expression of an integrin-mediated gene transfer vector in tracheal 
epithelial cells. Gene Ther 2000;7(2):139-52. 
 
27. Moffatt S, Wiehle S, Cristiano RJ. Tumor-specific gene delivery mediated by a 
novel peptide-polyethylenimine-DNA polyplex targeting aminopeptidase 
N/CD13. Hum Gene Ther 2005;16(1):57-67. 
 
28. Li H, Gray BD, Corbin I, Lebherz C, Choi H, Lund-Katz S, Wilson JM, Glickson 
JD, Zhou R. MR and fluorescent imaging of low-density lipoprotein receptors. 
Acad Radiol 2004;11(11):1251-9. 
 
29. Keller G, Schally AV, Gaiser T, Nagy A, Baker B, Halmos G, Engel JB. 
Receptors for luteinizing hormone releasing hormone expressed on human renal 
cell carcinomas can be used for targeted chemotherapy with cytotoxic luteinizing 
hormone releasing hormone analogues. Clin Cancer Res 2005;11(15):5549-57. 
 
30. Adams GP, McCartney JE, Tai MS, Oppermann H, Huston JS, Stafford WF, 3rd, 
Bookman MA, Fand I, Houston LL, Weiner LM. Highly specific in vivo tumor 
targeting by monovalent and divalent forms of 741F8 anti-c-erbB-2 single-chain 
Fv. Cancer Res 1993;53(17):4026-34. 
 
31. Zhao M, Beauregard DA, Loizou L, Davletov B, Brindle KM. Non-invasive 
detection of apoptosis using magnetic resonance imaging and a targeted contrast 
agent. Nat Med 2001;7(11):1241-4. 
 
32. Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific 
nanoparticles: theory to practice. Pharmacol Rev 2001;53(2):283-318. 
 
33. Vinogradov SV, Bronich TK, Kabanov AV. Nanosized cationic hydrogels for 
drug delivery: preparation, properties and interactions with cells. Adv Drug Deliv 
Rev 2002;54(1):135-47. 
 
34. Akerman ME, Chan WC, Laakkonen P, Bhatia SN, Ruoslahti E. Nanocrystal 
targeting in vivo. Proc Natl Acad Sci U S A 2002;99(20):12617-21. 
 93
35. Gao X, Cui Y, Levenson RM, Chung LW, Nie S. In vivo cancer targeting and 
imaging with semiconductor quantum dots. Nat Biotechnol 2004;22(8):969-76. 
 
36. Ballou B, Lagerholm BC, Ernst LA, Bruchez MP, Waggoner AS. Noninvasive 
imaging of quantum dots in mice. Bioconjug Chem 2004;15(1):79-86. 
 
37. Pluen A, Boucher Y, Ramanujan S, McKee TD, Gohongi T, di Tomaso E, Brown 
EB, Izumi Y, Campbell RB, Berk DA and others. Role of tumor-host interactions 
in interstitial diffusion of macromolecules: cranial vs. subcutaneous tumors. Proc 
Natl Acad Sci U S A 2001;98(8):4628-33. 
 
38. Zitzmann S, Ehemann V, Schwab M. Arginine-glycine-aspartic acid (RGD)-
peptide binds to both tumor and tumor-endothelial cells in vivo. Cancer Res 
2002;62(18):5139-43. 
 
39. Kunath K, Merdan T, Hegener O, Haberlein H, Kissel T. Integrin targeting using 
RGD-PEI conjugates for in vitro gene transfer. J Gene Med 2003;5(7):588-99. 
 
40. Nan A, Ghandehari H, Hebert C, Siavash H, Nikitakis N, Reynolds M, Sauk JJ. 
Water-soluble polymers for targeted drug delivery to human squamous carcinoma 
of head and neck. J Drug Target 2005;13(3):189-97. 
 
41. James MB, Giorgio TD. Nuclear-associated plasmid, but not cell-associated 
plasmid, is correlated with transgene expression in cultured mammalian cells. Mol 
Ther 2000;1(4):339-46. 
 
42. Glazer AN. Phycobiliproteins. Methods Enzymol 1988;167:291-303. 
 
43. Iyer SB, Hultin LE, Zawadzki JA, Davis KA, Giorgi JV. Quantitation of CD38 
expression using QuantiBRITE beads. Cytometry 1998;33(2):206-12. 
 
44. Chance JT, Larsen SA, Pope V, Measel JW, Cox DL. Instrument-dependent 
fluorochrome sensitivity in flow cytometric analyses. Cytometry 1995;22(3):232-
42. 
 
 94
CHAPTER IV 
 
PROXIMITY-ACTIVATED NANOPARTICLES: ENZYME-SPECIFIC 
MODIFICATION FOR TARGETED DELIVERY  
AND BIOSENSING 
 
 
RA Smith and TD Giorgio* 
 
Department of Biomedical Engineering 
Vanderbilt University, Nashville, TN 
 
Correspondence: 
Todd D. Giorgio 
Vanderbilt University 
Box 351620, Station B 
Nashville, TN  37235 
615-322-3756 (voice) 
615-343-7919 (fax) 
todd.d.giorgio@vanderbilt.edu 
 
 
 
 
 
 
 
This manuscript was prepared for submission in Nano Letters 
 95
4.1 Abstract 
We describe the development and in vitro performance of a modular nanoscale 
system capable of specific structural modification by enzymatic activity.  Due to its small 
physical size and adaptable characteristics, this system represents a versatile option for 
utilization in targeted delivery systems and biosensing.  Surface modification allows 
these proximity-activated nanoparticles to act as physiologically inert structures until 
activation and cleavage by tumor-specific enzymes.  We synthesized probes containing 
two distinct fluorescent species including a quantum dot base particle and fluorescently 
labeled cleavable peptide substrate.  Activity of these probes was monitored by gel 
electrophoresis with quantitative cleavage measurements made by fluorometric analysis.  
The model proximity-activated nanoparticles studied here exhibit significant 
susceptibility to cleavage by MMP-7 at physiologically relevant concentrations, with 
nearly complete cleavage of available substrate molecules after 24h.  This response was 
shown to be specific to MMP-7 enzyme activity, as cleavage is completely inhibited with 
the addition of EDTA.  Utilization of enzyme-specific modification is a sensitive 
approach with broad applications for targeted therapeutics and biosensing.  The 
versatility of this nanoparticle system is highlighted in its modular design, as it integrates 
characteristics for detection, biosensing, targeting, and payload delivery into a single, 
multifunctional nanoparticle structure.  
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4.2 Introduction 
 
4.2.1 Background 
Localized or specific delivery of therapeutics to diseased cells represents a 
historic paradigm shift in the treatment approach toward many disease states, including 
various types of cancer.  Traditional approaches utilize systemic administration of highly 
potent drugs in an attempt to eradicate neoplastic cells, often with significant toxic side 
effects.  Initial attempts at targeted delivery of these drugs have focused on the 
incorporation of small ligands to direct the therapy to a specific target site (1-4).  
However, the current generation of targeted therapies has not yet achieved highly specific 
targeting of tumors and emerging neoplasia through a single recognition mechanism 
(5,6).  Nonspecific binding and specific binding to nontarget cells compromise the 
therapeutic index of small molecule, ubiquitous cancer targeting ligands, and limit their 
applicability and efficiency as primary chemotherapeutic agents. 
An alternative targeting approach involves the use of molecules capable of 
activation following cleavage by tumor-specific enzymes.  These compounds have been 
incorporated into many structures ranging from in vivo imaging constructs (7-9) to 
chemically modified drug structures in the form of prodrugs (10-12).  These studies 
demonstrate the feasibility of tumor-specific enzyme interaction as a means of modifying 
the physical structure of delivered drugs and imaging constructs, and potentially enables 
targeted delivery of nanoparticle (NP) and other particulate drug carriers. 
A number of studies utilizing this approach have focused on the development of 
tumor-specific molecular imaging constructs cleavable by matrix metalloproteases 
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(MMPs) (9,13-16).  These reports have detailed peptide sequences with cleavage activity 
specific to a number of different MMPs, and to MMP-7 in particular.  The basis of the 
MMP-7 specific peptide substrate (RPLALWRS) utilized in one such report (15) is 
employed in this study to impart tumor-specific activity to our NP delivery system. 
Literature citations of tumor-specific cleavable constructs focus mainly on 
molecular imaging of enzyme activity and drug activation in vivo.  However, 
incorporation of these constructs into NPs or their application to target NP-based 
therapeutic delivery systems (forming proximity-activated (PA) NPs) has not yet been 
reported.  The use of NPs for this purpose has the inherent advantage of a large surface 
area to volume ratio, allowing conjugation of multiple active molecules.  Stable covalent 
conjugation of bioactive molecules such as enzymes (17,18), mAbs (19), peptides (20), 
and DNA (21,22) to the surface of NPs has been reported.  With small-molecule ligands 
such as the PA construct used here, many copies can be attached to the surface of the NP 
enabling multivalent interaction with target cells.  QDs offer the advantages seen in other 
NP systems with the added benefit of intense fluorescence characteristics for 
straightforward and highly sensitive detection and imaging.  These attributes impart the 
ability to integrate specific delivery, detection, imaging, and treatment characteristics into 
a single, multifunctional NP delivery vehicle. 
 
 
4.2.2 The role of MMP-7 in biological processes 
MMPs (including MMP-7) are a family of extracellular, zinc-dependent proteases 
that have a role in tissue breakdown and remodeling during both normal (e.g. 
angiogenesis, gut innate immunity) and pathological (e.g. inflammation, tumorigenesis, 
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metastasis) processes.  MMP-7 has been specifically implicated as an important 
facilitator of tissue remodeling due to its ability to cleave a variety of known substrates, 
including many ECM proteins and the latent forms of other MMPs (23).  Overexpression 
of MMP-7 has been directly correlated with enhanced tumorigenicity and tumor cell 
invasion using in vitro model systems (24).  It has been shown to be important in the 
progression of a number of tumors, notably those originating in the colon or in the breast 
(15).  Furthermore, MMP-7 has proven to have diagnostic and prognostic value, as 
expression is associated with poor outcome in esophageal (25), colon (26), and pancreatic 
(27) cancers.  The overexpression and significance of MMP-7 in the tumor cascade make 
this enzyme an attractive target for site-directed delivery vehicles. 
For tumor systems in which MMP-7 activity is known to modulate the course of 
the disease, MMP-7 is secreted even in the earliest stages.  Small, benign “precancerous” 
lesions, for example, exhibit MMP-7 secretion well before these lesions would be 
clinically detectable (28,29).  Furthermore, analysis of MMP-7 expression in human 
neoplasia revealed that enzyme mRNA appeared in the surrounding normal tissue in only 
a few isolated cases (23), suggesting highly specific enzyme expression in the immediate 
tumor vicinity.  The larger and more progressed these tumors become, the higher the 
MMP-7 levels tend to be.  This focused source of abundant extracellular MMP-7 is 
expected to provide ample activity for the in vivo application of PA NPs to cancer 
targeting.  
 The utilization of MMP-7 activity represents a potentially powerful approach 
toward specific targeting.  In this study, we describe the synthesis and in vitro 
performance of a NP probe capable of specific activation by MMP-7.  In addition, the 
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importance of quantitative analysis of construct performance is described in the context 
of in vitro and in vivo application.  These data provide the basis for a PA system capable 
of targeted delivery, detection, imaging, and therapeutic payload delivery from a single 
NP package. 
 
4.3 Methods 
 
4.3.1 Cleavable peptides and NP probes 
 A fluorescently labeled, PEGylated substrate for MMP-7 (HN-[Ahx]-PEG3400-
RPLALWRS-PEG5000-K(5-FAM)-[Ahx]-NH2; PA construct) was synthesized and 
purified by Anaspec (San Jose, CA).  This structure consists of the cleavable peptide 
substrate (RPLALWRS) flanked by polyethylene glycol (PEG) groups of 3400 and 5000 
g/gmol (to prevent nonspecific interactions) and aminohexanoic acid groups ([Ahx]) to 
serve as spacer molecules, as well as a fluorescent tag (5-FAM) for fluorometric 
detection.  To stabilize the substrate and prevent further modification at this site, C-
terminal amidation was performed during synthesis. 
 The N-terminal amine group of the substrate was conjugated to the surface of 
carboxylate QDs (585nm emission; Quantum Dot Corp., Hayward, CA) using 1-ethyl-3-
(3-dimethylaminopropyl)carbodiimide (EDC; Sigma).  Briefly, 250µl of QDs (7.5µM) 
was diluted to 1mM with 10mM borate buffer, pH 7.4.  80µL from a 10mg/mL stock 
solution of the cleavable substrate was then added to the solution, yielding a PA:QD 
molar ratio of 10.0:1 (lower bound) and 28.4:1 (upper bound).  57µl from a 10mg/ml 
stock solution of EDC was added and the mixture was stirred for 2h at room temperature 
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to complete the conjugation.  A schematic of the final QD-PA probe is shown in Figure 
4.1. 
Following conjugation, the mixture was purified by spin filtration in a 50,000 
nominal molecular weight limit (NMWL) cutoff device (Amicon Ultra-4, Millipore 
Corp.).  This process is expected to yield a QD probe product nearly free of unreacted 
components, as the intact PA structure is ~11,000 Da and any other fragments should be 
considerably smaller.  Three buffer exchanges were performed with 50mM borate buffer 
(pH 8.3) and the final conjugate was stored at 4°C.  The concentration of the final 
purified product was determined by measuring the absorbance at 575nm using a QD 
extinction coefficient of 400,000M-1cm-1.  As this value is a characteristic of the 
semiconductor core, the extinction coefficient is presumably unchanged by surface 
functionalization.  However, conjugation of molecules to the QD surface does have an 
effect on the fluorescence emission (i.e. quantum yield) of the final construct.  
 
 
4.3.2 MMP-7 cleavage assay 
 Studies were conducted to determine the susceptibility of both the PA and QD-PA 
constructs to exogenous MMP-7.  Active MMP-7 (Calbiochem) was added to 100µl of a 
50nM PA or QD-PA solution in borate buffer supplemented with 50µM ZnSO4.  The 
total concentration of MMP-7 was varied in these samples from 100nM to 5nM to reflect 
expected concentrations in vivo.  Samples were then incubated at 37ºC for various 
timepoints ranging from 1h to 48h.  Control studies involving QD-PA with no enzyme 
and with inactivated enzyme (by addition of 30mM EDTA, a known zinc chelator) were 
carried out simultaneously for direct comparison.  QD probes were purified from any  
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Figure 4.1. Enzyme sensitive QD-PA probes were synthesized by surface modification of AMP QDs.  
Carboxylate QDs (left, red) consist of a CdSe base with an amphiphilic (AMP) polymer shell containing 
multiple reactive carboxylate groups.  5-FAM labeled peptide substrate (green) was synthesized with 
proximal PEG3400 and distal PEG5000 polymers (black lines).   AMP QDs were activated with EDC before 
addition of the soluble PEGylated substrate.  The mixture was stirred for 2h and purified to remove any 
unreacted components, resulting in a modified, enzyme sensitive QD-PA probe (right).  The conjugation of 
many identical substrate molecules to the QD surface increases probe specificity by necessitating multiple 
enzymatic cleavages to successfully activate the particle.  Furthermore, this redundancy enables multivalent 
interaction of the activated probe with the target site. 
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cleavage products by spin filtration in a 50,000 NMWL cutoff device.  Samples were 
then assayed by gel electrophoresis and spectrofluorometry to determine the extent of 
construct cleavage from the QD surface. 
 
4.3.3 Cleavage measurement  
Gel electrophoresis 
Following the cleavage reaction, PA and QD-PA constructs were analyzed by gel 
electrophoresis to determine susceptibility to MMP-7.  PA constructs were analyzed on a 
10-20% gradient tris-tricine polyacrylamide gel (Life Gels).  Samples were loaded in a 
buffer containing 10% glycerol in tris-tricine running buffer (Life Gels).  Gels were then 
run under a 150mV voltage for ~1h to achieve optimal separation of the molecular 
species.  Unconjugated PA constructs (free in solution) were compared to cleaved PA 
constructs to straightforwardly visualize and confirm enzymatic activity against the 
substrate. 
Gel electrophoresis was also used to monitor the change in electrophoretic mobility of 
the QD construct.  QDs subjected to the cleavage reaction were assayed against native 
AMP QDs, uncleaved QD-PA constructs, and QD-PA + EDTA on a 0.8% bufferless 
agarose gel (E-Gel, Invitrogen Corp.).  Differences in electrophoretic mobility were used 
to qualitatively assess construct synthesis (the difference between AMP and QD-PA 
mobilities), construct cleavage (QD-PA and cleaved QD-PA), and cleavage specificity 
(cleaved QD-PA and QD-PA + EDTA). All gels were imaged for fluorescence on a 
BioDoc-It imaging system (UVP Inc.).  
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Fluorescence measurement 
Fluorescence spectroscopy (Perkin-Elmer LS 50B) was used to monitor the progress 
of the cleavage reaction.  Prior to experimentation, a fluorescence spectrum of the QD-
PA construct was taken at 488nm excitation.  This spectrum was used to quantify both 
the fluorescence intensity of the QD base (at 585nm) as well as the labeled PA molecules 
on the QD surface (at 519nm).  As these spectra only minimally overlap, they are easily 
separated when present together in a single sample.  
Following cleavage and purification, the fluorescence spectra of the cleaved QD-
PA constructs were measured.  The peak values at 519nm and 585nm were directly 
compared to the spectra of control, uncleaved QD-PA particles to estimate the extent of 
PA construct cleavage following MMP-7 treatment. 
 
4.3.4 Quantitative fluorescence analysis 
 A quantitative determination of PA construct cleavage was made by digital 
analysis of gel electrophoresis images.  Briefly, gel images were obtained on a BioDoc-It 
imaging system as JPEG files and visually analyzed in Doc-It LS software (UVP Inc.).  
This software platform was used to detect, define, and draw “gates” around individual 
bands.  Each band was then electronically cut from the image, saved as a separate JPEG 
file, and loaded into MATLab.   
For digital image analysis, these separate images were loaded into a MATLab 
script designed to calculate quantitative image parameters.  The composite fluorescence 
intensity for each band (i.e. each individual image) was calculated by summing the 
measured intensity of each pixel contained in the image.  These composite intensities 
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were then summed to determine the total fluorescence of all bands within each lane.  The 
relative percentage contained in each band was obtained by comparing its composite 
fluorescence to that of the total for the lane.  The MATLab code used to perform these 
calculations is shown in Appendix 4A. 
 Fluorescence measurements of QD-PA constructs were analyzed to quantitatively 
determine the extent of PA construct cleavage from the QD surface.  Spectra measured 
by fluorescence spectroscopy were scaled to normalize QD peak fluorescence (~585nm) 
between all samples.  The peak values for PA construct fluorescence (~519nm) were then 
recorded for each sample.  Using samples with no enzyme as a control (defined as 0% 
cleavage), the extent of PA construct cleavage for each sample was determined by 
calculating the ratio of PA construct fluorescence between cleaved and uncleaved 
(control) samples.  These quantitative measurements were then scaled to account for the 
percent of cleavable PA construct contained in the original sample (from values obtained 
by quantitative analysis of the polyacrylamide gels previously described). 
 
 
4.3.5 Statistics 
Statistical significance of experimental populations was assessed using an upaired 
t-test and determined by SigmaStat (Jandel Scientific Software).  Differences were 
termed significant for p < 0.05. 
 
4.4 Results 
4.4.1 In vitro cleavage of the PA construct 
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The PA construct is highly susceptible to cleavage by MMP-7.  Prior to 
conjugation to the QD surface, PA constructs were assayed for susceptibility to 
enzymatic activity.  Gel electrophoresis analysis of unconjugated PA construct confirms 
specific cleavage of these molecules by MMP-7 (Figure 4.2).  Lanes 1 and 2 confirm the 
presence of the intact fluorescently labeled PA structure.  These bright low mobility 
bands are nearly extinguished after 24h exposure to MMP-7.  This cleavage also results 
in the generation of a very bright high mobility band corresponding to the low molecular 
weight labeled cleavage product (Figure 4.2, lanes 3 and 4).  PA construct cleavage was  
completely abolished by the addition of 30mM EDTA (a known zinc chelator; Figure 4.2, 
lanes 5 and 6), as the band corresponding to the intact PA construct is present in these 
wells.  These results are consistent with the near complete proteolysis of the PA construct 
at the site of the MMP target peptide and inhibition of the zinc-dependent MMP-7 
enzyme by EDTA. 
A quantitative analysis was also made of the gel electrophoresis images obtained 
from these samples.  MATLab was used to calculate the composite intensity of all pixels 
within each band (the sum of individual intensities for each pixel), as well as the 
composite intensity within each lane.  Table 4.1 contains representative values obtained 
from the gel pictured in Figure 4.2.  From these values, we determined the percentage of 
PA construct contained in each sample.  Control, uncleaved soluble PA construct 
contains 35.6 ± 3.4% intact PA structure (n = 4).  After 24h exposure to 100nM MMP-7, 
87 ± 0.7% of the initial PA construct was cleaved (statistically significant, p < 0.001) 
based on the residual 4.6 ± 0.7% intact PA construct, confirming the high susceptibility 
of the PA construct to MMP-7 proteolysis.  MMP-7 mediated cleavage was completely  
 106
  
PA 
construct 
     1          2          3        4          5         6    
 
 
 
 
 Construct 
motion  
 
 
 
 
 
 
Figure 4.2. Cleavage of the soluble, unconjugated PA construct by MMP-7 was confirmed by gel 
electrophoresis.  Samples of soluble PA construct were incubated for 24h with 100nM MMP-7 and 
analyzed on a 10-20% gradient tris-tricine polyacrylamide gel.  Lanes 1 and 2 represent unconjugated PA 
construct prior enzymatic exposure as a control.  The bright, low mobility band (identified by the horizontal 
arrow) represents the intact PA structure, while the other fluorescent bands presumably correspond to 
unreacted fluorescent species and intermediates not removed during purification.  Nearly all of the PA 
construct is cleaved after 24h exposure to MMP-7 (Lanes 3 and 4), suggesting high susceptibility of the 
construct to MMP-7 activity.  This activity is completely inhibited with the addition of 30mM EDTA (a 
zinc chelator) to the samples (Lanes 5 and 6).  Inhibition of MMP-7 activity results in no measurable 
cleavage of the PA constructs.  The gel pictured is representative of three independent measurements. 
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 PA Construct 
Fluorescence 
Total Sample 
Fluorescence 
% Intact PA 
Construct 
% Cleavable 
PA Construct 
Lane 1 0.5424 1.3707 39.5% N/A 
Lane 2 0.3094 0.9722 31.8% N/A 
Lane 3 0.0592 1.1591 5.1% 30.6% 
Lane 4 0.0607 1.4803 4.1% 31.6% 
Lane 5 0.3113 0.8443 36.9% N/A 
Lane 6 0.3354 0.9852 34.0% N/A 
 
Table 4.1. The PEGylated peptide substrate is highly susceptible to cleavage by MMP-7.  Cleavage was 
measured by optical analysis of polyacrylamide gel images (Figure 1).  Each band was identified as a 
region of interest, electronically cut from the image, and loaded into a MATLab script to calculate the 
fluorescence intensity for the band.  The composite intensity of each well was then calculated by summing 
the intensities of each constituent band.  These results correspond to the gel image in Figure 2.  Control, 
uncleaved PA samples (Lanes 1 and 2) contain an average of 35.7% intact PA structure.  24h exposure to 
100nM MMP-7 results in a reduction of intact PA structure to an average of 4.6%.  The percentage of 
cleavable construct (31.1% average) was then calculated by subtracting the construct remaining after 24h 
MMP-7 exposure from the average percentage measured in the uncleaved samples.  Addition of EDTA to 
the samples (Lanes 5, 6) results in strong inhibition of PA construct cleavage, as the percentage of intact 
construct (35.5% average) is nearly identical to that of control samples in the absence of MMP-7.  
Quantitative analysis for all experiments (n ≥ 3) with statistical analysis appears in the Results. 
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blocked by the addition of EDTA.  After 24 exposure to 100nM MMP-7  supplemented 
with 30mM EDTA, 35.5 ± 2.0% of the PA construct remained intact, a value nearly 
identical to the amount measured in control samples in the absence of MMP-7 (p = 
0.966).  
 
4.4.2 QD-PA construct synthesis 
 The surface of AMP QDs was successfully modified with the PA construct.  We 
characterized the electrophoretic mobility of our QD probes to determine the success of 
the surface modification reaction.  Figure 4.3 shows the difference in mobility between 
unmodified AMP QDs (lanes 3, 8) and those modified with the PA structure (lanes 4, 9).  
Conjugation of the PA construct to the QD surface results in a significant increase in MW 
of the probe and a corresponding decrease in electrophoretic mobility. 
 QD-PA synthesis was further confirmed by measuring the fluorescence spectra of 
the resulting conjugates.  Following conjugation and purification, the fluorescence 
spectra of the QD-PA constructs were measured (Figure 4.4, control QD-PA).  These 
spectra reveal fluorescence maxima at ~520 and ~590nm, corresponding to the emission 
maxima of the 5-FAM labeled PA construct (~519nm) and of the QD base (~585nm).  
The peak values measured at these wavelengths suggest a high level of PA construct 
conjugation to the QD surface.  There was no significant photobleaching of either 5-FAM 
or QD over the course of the measurements.  Furthermore, additional studies revealed no 
significant change in QD fluorescence intensity (at ~585nm) upon PA cleavage from the 
surface (data not shown).   
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Figure 4.3. The surface of AMP QDs was successfully modified with the cleavable PA construct.  
Electrophoretic mobility of QD conjugates was assessed on a 0.8% bufferless agarose gel.  Mobility of 
QDs modified with the cleavable PA construct (lane 4, diffuse band) is reduced compared to that of 
unmodified AMP QDs (lane 3).  The conjugation of PA construct to the surface modifies the molecular 
mass and surface charge of the construct, resulting in reduced mobility.  24h exposure of the QD-PA 
conjugates to MMP-7 (lane 5) leads to a partial recovery of mobility, suggesting significant cleavage of the 
attached PA structure.  Increased mobility after exposure to MMP-7 can be completely inhibited by the 
addition of 30mM EDTA (lane 6), suggesting the presence of intact PA construct on the QD surface.  This 
image is representative of three independent trials. 
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Figure 4.4. Fluorometric measurements reveal a significant PA cleavage from the QD surface after 24h 
exposure to 100nM MMP-7.  The presence of two peaks in the uncleaved QD-PA also confirms 
conjugation of the PA construct to the QD surface.  Fluorescence spectra of QD-PA constructs from 500-
625nm were monitored by fluorometry, with an excitation wavelength of 488nm (5nm slit).  Spectra were 
scaled to normalize QD fluorescence intensity (~585nm) among all samples.  QDs reacted with PA 
construct and purified to remove unbound material possess two fluorescence emission peaks consistent 
with colocalized QD and PA construct fluorescence.  Exposure to MMP-7 (dashed line) results in reduced 
5-FAM fluorescence intensity at ~519nm when compared to control, uncleaved QD-PA samples (solid 
line), suggesting significant cleavage of the labeled PA construct from the QD surface at the site of the 
MMP-7 target substrate.  Figure is representative of multiple independent measurements with varying 
MMP-7 concentrations and incubation times.  Results shown are representative of n ≥ 3 trials for all 
experimental groups. 
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4.4.3 QD-PA cleavage by MMP-7 
 PA constructs retain their enzymatic susceptibility after conjugation to the QD 
surface.  Surface-functionalized QD-PA constructs were treated with 100nM MMP-7 
under the same conditions as unconjugated PA constructs.  Agarose gel analysis of these 
samples (Figure 4.3) reveals a partial recovery of mobility following MMP-7 treatment 
(lanes 5, 10), consistent with a reduction of surface-associated molecular mass mediated 
by proteolytic cleavage.  Mobility recovery is not complete, consistent with persistence of 
the proximal portion of the PA construct on the QD surface after proteolytic cleavage of 
the distal PA component.  MMP-7 mediated increase in electrophoretic mobility is  
reversed with addition of 30mM EDTA during the cleavage (lanes 6, 11), suggesting 
inhibition of MMP-7 activity by EDTA.  Changes in relative mobilities provide evidence 
of successful QD surface functionalization, subsequent proteolytic degradation, and 
inhibition of enzyme activity expected in this system. 
Enzymatic cleavage was also monitored by measuring changes to the fluorescence 
spectra of the QD-PA constructs after incubation with MMP-7.  Following the enzymatic 
exposure, QD constructs were purified from cleavage products by spin filtration, and the 
fluorescence spectrum of purified QDs was measured (Figure 4.4).  Relative to control, 
uncleaved QD-PA constructs, these spectra reveal a reduced fluorescence peak at 519nm 
corresponding to the labeled, intact QD-PA construct.  This result is consistent with gel 
electrophoresis images and computed results, and suggests significant proteolysis of the 
PA construct at the site of the MMP-7 target peptide and subsequent removal of cleavage 
products, including the 5-FAM fluorophore from the QD surface. 
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 Fluorescence measurements were used to produce a quantitative analysis of PA 
construct cleavage.  These measurements (Figure 4.5) confirm significant cleavage of the 
PA construct from the QD surface.  Treatment of the QD-PA constructs with 100nM 
MMP-7 resulted in steadily increasing cleavage with increased incubation time, reaching 
a plateau after 24h (31.8 ± 5.4% cleavage, n ≥ 3 for all timepoints).  Measured cleavage 
values are highly dependent on incubation time, and follow an exponential rise to 
maximum curve describing traditional enzyme kinetics.  These measured cleavage values 
were then scaled to account for the percentage of cleavable PA construct contained in the 
original sample (from quantitative analysis of gel electrophoresis).  This scaling revealed 
nearly complete proteolysis of the cleavable PA construct on the QD surface after 24h  
(90.9 ± 15.4% cleavage), consistent with cleavage of unconjugated PA constructs under 
the same conditions (87.1 ± 0.7% cleavage). 
Cleavage of the PA construct from the QD surface was also significantly 
influenced by initial MMP-7 concentration.  Results from MMP-7 concentrations ranging 
from 100nM to 5nM are shown in Figure 4.5.  Although the cleavage response measured 
for each MMP-7 concentration follows the same general trend, the extent of cleavage is 
markedly altered, as cleavage declined as MMP-7 concentration was lowered.  
Furthermore, additional analysis of these results (Figure 4.6) reveals that the initial 
cleavage rate (t<6h) plateaus at an MMP-7 concentration below 100nM, as no additional 
significant cleavage is measured as enzyme concentration is increased from 10nM to 
100nM.  A minimum of three independent trials was performed for each timepoint and 
MMP-7 concentration.
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Figure 4.5. QD-PA probes are highly susceptible to MMP-7 activity.  Fluorescence spectra of control, 
uncleaved QD-PA structures were compared to those of samples incubated with MMP-7.  Fluorescence 
intensities corresponding to the QD and PA construct were then analyzed and scaled to quantitatively 
determine the extent of proteolytic cleavage of the PA construct from the QD surface.  Measured cleavage 
was highly dependent on incubation time, steadily increasing to reach a maximum scaled value of 90.9 ± 
15.4% after 24h incubation with 100nM MMP-7 (hollow triangles).  Incubation with 10nM MMP-7 
(hollow squares) resulted in reduced cleavage measurements for nearly all timepoints, although a 
statistically relevant difference compared to 100nM was only present at 24h. 5nM MMP-7 (solid circles) 
resulted in statistically reduced cleavage for all timepoints measured.  Cleavage was completely inhibited 
with the addition of EDTA (solid diamond).  The right vertical axis reflects the loss in 5-FAM fluorescence 
from the QD while the left vertical axis corrects that measurement to yield the percentage of surface-bound 
PA constructs cleaved.  n ≥ 3 for all concentrations and timepoints. 
 114
Log[
1 1
%
 c
le
av
ag
e
0
10
20
30
40
50
60
70
or
re
ct
ed
)
15
20
1h 
3h 
6h 
 
Figure 4.6. Cleavage of PA construct from the Q
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ncentrations and timepoints. 
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4.5 Discussion 
 Although the importance of therapeutic targeting has been acknowledged for 
more than two decades, few viable options for targeted therapy have been successfully 
implemented.  Many treatment regimens continue to rely on bolus systemic doses that 
compromise the drug concentrations delivered to target tissue based on systemic toxicity 
resulting form specific and nonspecific delivery to nontarget cells (30).   
The power of effective in vivo drug targeting is exemplified by the astounding success of 
trastuzumab (Herceptin), a monoclonal antibody that targets the HER2 receptor that is 
overexpressed on the surface of some breast cancers.  Other approaches have attempted 
to use small ligands to direct administered therapies specifically to the target site(s) that 
present the corresponding receptor.  However, nonspecific binding and specific binding 
to nontarget cells often compromises the therapeutic index of small molecule targeting 
ligands, limiting their applicability and efficiency as primary targeting agents (31,32).  
These obstacles compromise the large investment in targeting ligand discovery and the 
availability of robust approaches for screening new molecular targeting ligands. 
This study describes the development and in vitro performance of a new family of 
multifunctional nanoscale constructs capable of overcoming the obstacles that 
compromise in vivo small molecule drug targeting.  The approach described here 
presumably enables display of the targeting ligand only in the immediate vicinity of the 
target tissue.  Demonstrated in this work is the feasibility of nanoparticle activation by 
MMP-7, a proteolytic enzyme secreted by a number of tumors.  With potential 
applications for targeted therapy as well as in vitro and in vivo biosensing, the ‘smart’ NP 
probes developed here represent a powerful, versatile platform combining detection, 
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biological activity sensing, targeting, and treatment characteristics into a single, 
multifunctional nanoscale construct. 
The construct developed and assessed in this work initially presents as a 
PEGylated nanoparticle with low nonspecific binding as predicted from previous studies 
(33-35).  PEGylation is provided by a PA construct, essentially composed of a PEG chain 
interrupted by the peptide target of MMP-7 proteolysis.  Cleavage of the internal peptide 
liberates the distal PEG and part of the peptide (along with a fluorophore, in this work, 
for assessment of cleavage).  Proteolytic modification can presumably be used to enable 
access to a small molecule ligand previously concealed near the nanoparticle surface.  
Effective proximity activated targeting will likely be modulated by many molecular 
factors, including the relative characteristics of the distal and proximal PEGs on the PA 
construct and the PEG (or other molecular spacer) that displays the ligand from the 
nanoparticle surface. 
Proximity activated targeting requires the colocalization of the cleavable mask 
and the targeting ligand, necessitating a particulate approach.  In the exemplar described 
here, the nanoparticle is a QD, used to provide a fluorescent beacon for performance 
assessment.  Subsequent work will employ this construct, amended to include a targeting 
ligand, to assess proteolytically activated targeting in vitro and in vivo by quantitative 
fluorescence measurements and fluorescence imaging.  The appropriateness of QDs for 
clinical applications remains unknown, but the proximity activated targeting approach 
described here can be applied to other nanostructures approved for use in humans.  These 
nanomaterials include iron oxide nanoparticles for magnetic resonance (MR) image 
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contrast enhancement and drug delivery structures such as polymers, liposomes, 
polymersomes and gene delivery vehicles. 
Successful delivery of therapeutics or particles to desired site(s) can, in principle, 
be accomplished by both passive and active targeting principles.  Passive targeting 
reduces recognition by, and nonspecific interaction with nontarget sites such as healthy 
cells while active targeting mechanisms act to directly increase the affinity of the delivery 
system to the target site.  The QD-PA systems described here minimize undesirable 
interactions with nontarget tissues via a passivating hydrophilic PEG surface coating.  
This coating has been used successfully in other in vitro and in vivo applications to 
reduce unintended nonspecific interactions of delivered drugs and particles (33-35).  The 
novel approach described here also employs an active targeting mechanism (cleavage by 
MMP-7) to activate ligand display only in the vicinity of the target, thus presumably 
maximizing interaction with target cells.  This two event requirement for targeting 
increases the effective sensitivity of the construct by keeping the passive PEG coating 
intact until the particle reaches the immediate proximity of the target.  Thus, NP-PA 
constructs may be able to achieve much greater target selectivity over both conventional 
and single-modality targeted delivery systems. 
  
PA and QD-PA cleavage 
 Our initial gel electrophoresis characterization of the PA structure reveals 
significant susceptibility of this molecule to specific MMP-7 activity.  These results are 
consistent with previous reports detailing specific cleavage of the peptide substrate by 
MMP-7 (15).  Furthermore these results establish that specific activity is retained after 
modification of the peptide with spacer ([Ahx]) and PEG molecules.  Additional studies 
 118
demonstrate that PA constructs retain their MMP-7 susceptibility following conjugation 
to the QD surface.   
While cleavage measured by gel electrophoresis can detect susceptibility of PA 
and QD-PA constructs to MMP-7 activity, these results are not direct quantitative 
measures of construct cleavage.  Traditional gel electrophoresis typically yields results 
appropriate for straightforward qualitative comparisons.  However, further analysis of 
this gel data is able to produce some quantitative results.  Pixel by pixel optical analysis 
of polyacrylamide gel data (Figure 4.2) using MATLab provided additional insight 
unavailable by visual inspection alone (Table 4.1).  This analysis revealed that only 
approximately one-third (~35%) of the original PA construct sample fluorescence is 
produced by intact PA structure.  The remainder of the sample likely consists of 
unreacted fluorescently labeled starting material and labeled intermediates not removed 
during purification of the PA structure.  These impurities are also expected to attach to 
the QD surface during the conjugation reaction, resulting in QD-PA conjugates with a 
significant level of non-cleavable substrate on the surface.  In the current study, cleavage 
measurements were appropriately scaled to account for these labeled impurities.  
However, subsequent work will employ robust purification methods (e.g. HPLC) to 
remove these impurities prior to conjugation, thus maximizing construct activity and 
sensitivity.  
Results of QD-PA cleavage obtained by agarose gel electrophoresis, however, are 
not capable of producing similar quantitative results.  The polyacrylamide gels studied 
previously contain PA structures labeled by a single fluorophore (5-FAM).  QD-PA 
constructs, on the other hand, contain both 5-FAM as well as QD fluorescence emissions.  
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Thus, the grayscale images obtained from these gels represent the composite fluorescence 
of both fluorophores contained in the QD-PA structure.  A similar quantitative analysis of 
these images is not possible as these fluorescence emissions cannot be easily separated 
without simultaneous analysis of multiple images obtained using filters for each 
fluorophore. 
 
Quantitative analysis of cleavage measurements 
Results obtained by fluorometry, however, are able to easily separate 5-FAM and 
QD emissions based on wavelength and provide data appropriate for quantitative 
analysis.  Fluorometric analysis (Figure 4.4) confirms the results obtained by gel 
electrophoresis, verifying both successful conjugation of the PA construct to the QD 
surface and subsequent cleavage by MMP-7.  This data also reveals system 
characteristics not accessible through qualitative techniques.  Analysis of uncleaved QD-
PA samples reveals a high level of 5-FAM fluorescence associated with each QD.  As 
each 5-FAM molecule results in lower fluorescence emission intensity than a single QD, 
this data suggests that multiple PA constructs are conjugated to the QD surface.  
Subsequent fluorescence spectra taken following MMP-7 cleavage confirm significant 
cleavage of the intact PA construct from the QD surface as well as cleavage inhibition by 
EDTA, singling out specific MMP-7 mediated activity as the source of reduced 
fluorescence intensity.  Further analysis of these constructs by fluorometry and 
spectrophotometry reveal that the level of substitution ranges from 0.74 (lower bound) 
and 2.2 (upper bound) PA constructs per QD (data not shown).  The current conjugation 
level may be too low to support effective masking of underlying ligands, however several 
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methods are being investigated to increase surface substitution.  Nonetheless, the studies 
presented here demonstrate the viability of the PA approach.   
The performance of the multifunctional NP system described here has some 
characteristics of conventional materials.  Our studies also reveal several variables 
strongly modulating QD-PA cleavage.  Initial cleavage measurements (Figure 4.5) reveal 
a strong dependence on enzyme concentration and exposure time.  Furthermore, these 
results demonstrate the expected shape and saturation characteristics of traditional 
enzyme kinetics.  In addition, the dose-response curve (Figure 4.6) shown here follows an 
apparently sigmoidal shape, representative of many well-known enzyme and ligand 
binding systems.  These characteristics enable predication of the system response based 
on the MMP-7 concentration and exposure time, critical factors in establishing in vivo 
performance of the construct.  Measurements such as these will be useful in future studies 
for optimization of the QD-PA structure, as they enable assessment of the contribution of 
alternate configurations to the proteolytic sensitivity of the construct. 
 From previous analysis in the literature, the Km of the unmodified PA substrate is 
26µM (36).  Thus, at substrate concentrations below this value, PA cleavage is expected 
to be independent of MMP-7 concentration.  Bulk PA concentrations used in the current 
study range from 37.5 – 100nM.  However, these studies demonstrate the effect of MMP-
7 concentration on construct cleavage.  Additional analysis of experimental conditions 
reveals a likely explanation for these results.  At the given substrate concentration, and at 
low MMP-7 concentrations (e.g. 5nM and 10nM), MMP-7 is the limiting reagent.  At 
higher MMP-7 concentrations (e.g. 100nM), MMP-7 concentration meets or exceeds 
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substrate concentration.  Thus, cleavage behavior transitions from a regime where MMP-
7 is the limiting component to a regime where PA is the limiting component. 
Additional characteristics affecting probe performance, including kinetic 
measures such as cleavage rate, can be obtained only from quantitative data.  For 
example, results confirm that MMP-7 concentration significantly affects the overall 
cleavage and cleavage rate (average cleavage over the first three timepoints) of the QD-
PA probes (Figure 4.6).  Furthermore, these results suggest that proteolytic susceptibility 
saturates at MMP-7 concentrations above 10nM.  Thus, at enzyme concentrations at or 
above this threshold, QD-PA probes are expected to demonstrate maximal activity. 
Quantitative analyses such as this are especially important for predicting 
performance in in vivo applications where enzyme concentration is not under direct 
control.  For example, MMP-7 concentration can vary widely, with overexpression noted 
in various tumor phenotypes (15).  While few quantitative measures of MMP-7 
concentration have been performed, previous studies have utilized MMP-7 concentrations 
of up to 100nM in vitro (37,38), while others have measured comparable concentrations 
of additional MMPs in vivo (39).  This evidence suggests possible MMP-7 concentrations 
in tumor of at least 50nM, corresponding with the levels utilized in the current study.  At 
these predicted MMP-7 concentrations, the QD-PA probes described here require <6h for 
activation (defined as 50% cleavage), with significant activity reached within 3h. 
As particle activation time and tissue residence time (i.e. particle velocity) are 
competing factors, this ratio is an important consideration with potential for significant 
impact on in vivo utility of QD-PA constructs.  If activation time is long compared to 
residence time (e.g. for vascular targets), then the NP will presumably be transported 
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away during activation and before specific binding can occur.  In this case, PA delivery is 
no worse than current targeted approaches.  However, the small size and surface 
passivation (PEGylation) of the QD-PA construct combine to create a construct likely 
capable of extravasation, enabling access to targets within the tissue.  In this 
compartment, particle velocity is likely to be small, allowing ample time for particle 
activation. 
The modular structure of the QD-PA constructs provides multiple parameters for 
performance optimization, with various factors presumably modulating the overall 
activity of the construct.  PEG length is one variable with potential to significantly affect 
multiple characteristics including enzyme susceptibility (by limiting enzyme access to the 
substrate), nonspecific binding limitation, effective ligand concealment (in future 
structures), and particle mobility.  Additional structural parameters including enzyme 
substrate configuration, ligand selection, and QD ligand surface density (number of 
molecules conjugated to the QD surface) can also directly affect probe performance.  
Thus, the relative importance of these factors must be taken into account during 
optimization.  Performed correctly, tailoring of these multiple characteristics enables 
optimization of probe performance for the requirements of both in vitro and in vivo 
systems.   
The use of NPs as a base for this system imparts multiple characteristics not 
available with molecular systems alone.  Chief among these is a significant inherent 
surface area to volume ratio, presenting capacity for conjugation of multiple targeting 
molecules.  Surface conjugation is further advantaged by the availability of a large 
number of functional groups on the NP surface, enabling the colocalization of multiple 
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functionalities as well as multivalent target interaction of the NP construct.  Additional 
properties of the modular base particle can also be utilized to impart desirable 
characteristics to the NP construct, including significant particle mobility, payload 
delivery, and an array of imaging options ranging from fluorescence (as for QDs) to CT 
contrast (e.g. gold nanoclusters).   
This study forms the basis for a new family of modular nanoscale constructs 
capable of both targeted therapeutic delivery and sensitive detection of biological 
phenomena (e.g. enzymatic activity).  Taken together, our results demonstrate the 
successful synthesis of a sensitive PEGylated substrate for MMP-7 activity, and its 
incorporation into a versatile system displaying detection, sensing, targeting and 
treatment characteristics in a single nanoscale platform.  These probes are sensitive to 
low, physiologically relevant MMP-7 concentrations and represent an alternative 
approach to small-molecule targeting and biosensing systems.  Substitutions to the 
specific mechanism for activation in the proximity of the target site or the incorporation 
of additional targeting molecules enable an array of new nanoscale constructs with the 
potential to significantly impact targeted therapy. 
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4.7 APPENDIX 4A 
 
MATLAB SCRIPT FOR QUANTITATIVE GEL  
ELECTROPHORESIS ANALYSIS 
 
 
clear all 
 
for i=1 
   A=imread([num2str(i) '.tif']); 
   A=double(A(:,:,2)); 
   C(i,:)=[max(A(:)) min(A(:)) mean(A(:)) std(A(:))]; 
end 
 
background=C(3); 
clear C 
for i=2:300 
    A=imread([num2str(i) '.tif']); 
    A=double(A(:,:,2)); 
    A=A-background; 
    B=A(find(A>0)); 
    pixels=length(B); 
    C(i,:)=[max(B(:)) min(B(:)) mean(B(:)) std(B(:)) 
pixels sum(B)]; 
    disp('Max') 
 disp(C(:,1)) 
  disp('Min') 
 disp(C(:,2)) 
  disp('Mean') 
 disp(C(:,3)) 
  disp('Standard Dev') 
  disp(C(:,4)) 
  disp('pixels') 
  disp(C(:,5)) 
  disp('composite intensity') 
  disp(C(:,6)) 
 end 
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CHAPTER V 
 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
5.1 Summary 
The work presented here traces the path of a specific targeting approach from the 
in-depth analysis of a specific cell surface protein to the design, synthesis, and in vitro 
performance of a targeted nanoscale construct.  Complete characterization of any 
targeting system must begin with a comprehensive analysis of the target molecule.  The 
current study utilizes fluorescently labeled mAbs to probe the surface of target cells in an 
in vitro environment to locate and quantify relevant target molecules (the CD13 protein).  
Studies were successful in quantifying the target concentration on these cells, as well as 
assessing the modulatory effects of several stimulating factors – exposure to low-dose 
ionizing radiation and incubation with the cytokines TNF-α and TGF-β1.  Cell targets in 
an in vivo environment, however, are subjected to a range of possible modulatory factors.  
While the current study is unable to fully explore these options, it does reveal the 
significant effects these factors can evoke, and highlights the importance and utility of 
quantitative target analysis 
By combining the features of nanoscale constructs with fluorescence detection, 
we were able to design a versatile multifunctional probe compatible with detection and 
imaging techniques readily available in many biological laboratories (e.g. fluorescence 
microscopy, fluorometry, flow cytometry).  Work contained in this dissertation 
demonstrates the sensitivity and intense fluorescence emission of the QDs utilized as the 
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base of the targeting construct; a characteristic that facilitates detection of these probes at 
concentrations well below those required for conventional fluorophores.  This ability 
presumably extends the capability of this system to detect rare event populations not 
detectable by traditional fluorescence techniques.  Furthermore, the modularity conferred 
by the nanoparticle base enables customization of the construct for compatibility with a 
range of available detection methods from fluorescence (e.g. with QDs) to CT (e.g. with 
gold nanoclusters). 
While presenting appealing characteristics, these native nanostructures do not 
possess any inherent activity.  Surface functionalization was assessed as a means to 
mediate specific interaction with the in vitro environment.  We were able to successfully 
conjugate multiple ligands to the surface of these nanoparticles, conferring a range of 
functionalities including reduced nonspecific interaction, targeted binding to cellular 
proteins, and specific susceptibility to enzymatic activity.  In vitro analysis of these 
constructs reveals the capacity of surface functionalization to impart specific activity and 
significantly alter the characteristics of the entire nanoscale construct.  Combining the 
functionality of surface-conjugated ligands with the physical and chemical characteristics 
of the underlying nanoparticle provides the basis for a versatile multifunctional probe 
capable of specific interactions with the immediate environment. 
While only a handful of interactions are studied here, this work reveals the utility 
of small molecule ligands to impart specific activity and highlights the potential of 
nanoparticles as a base for these interactions.  These studies trace the development of a 
targeted nanoscale probe from characterization of the target protein through synthesis and 
in vitro performance analysis of the targeted constructs.  The strategies put forth in this 
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dissertation are highly effective in providing specific activity at target sites.  Individually, 
these approaches can provide significant utility for both targeted delivery and biosensing.  
While these studies do not describe the characteristics of the complete PAT construct, 
individual elements assessed here lay the groundwork to achieve this goal.  In addition, 
multiple levels of construct modularity enable customization of the targeting system to 
adapt to different targets, detection modalities, and delivery strategies.  These 
advancements have the potential to provide a versatile system capable of providing 
features for targeted binding, imaging, biosensing, and therapeutic payload delivery in a 
single nanoscale particle, with the sensitivity, efficacy, and modularity not available in 
similar targeting strategies. 
 
5.2 Future Work 
While the studies toward the specific aims here comprise the entirety of this 
dissertation, the ultimate vision is the creation of a multifunctional NP with both tumor 
targeting and PA capability.  In many cases, effective specific delivery requires more 
than a single recognition mechanism.  The work outlined in this dissertation describes the 
components necessary to achieve this goal – design and implementation of a 
multifunctional proximity activated, targeted (PAT) system.  Steps toward the realization 
of such a multifunctional surface-modified NP are described below. 
 
 
5.2.1 Optimization 
Before the success of a PAT system can be realized, each component targeting 
approach must be optimized to ensure maximal sensitivity and efficacy.  One major 
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variable in targeting performance is the length of the PEG chains utilized for both 
specific targeting (i.e. PEG-NGR) and in the PA component (i.e. PEG-peptideMMP7-PEG).  
Initial PEG lengths were chosen to minimize steric effects (spacing from the nanoparticle 
surface) and to achieve surface passivation.  Variation of PEG chain length has the 
potential to significantly modulate both specific binding and enzyme susceptibility.  
However, as overall particle size is expected to significantly affect construct mobility in 
vivo, optimization of PEG chain length should be performed to maximize targeting 
efficiency while minimizing overall construct diameter. 
A second major variable subject to optimization is the surface density of each 
targeting component.  In the studies presented here, reaction conditions were chosen to 
maximize ligand conjugation.  However, modulation of ligand surface density is expected 
to be a considerable factor for overall targeting efficiency.  The effects of ligand density 
must be analyzed in the context of specific binding effects and susceptibility to enzyme 
cleavage.  These results can then be used as the basis to optimize ligand density in the 
composite PAT system.  
Molecular modeling of these characteristics has the potential to streamline the 
optimization process.  Detailed molecular modeling of the contributions of each variable 
(e.g. PEG, enzyme substrate, ligand density) has the potential to predict performance, 
enabling optimization of structural characteristics while minimizing the experimental 
burden. 
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5.2.2 PAT synthesis 
While the efficacy of each targeting strategy (i.e. specific homing to target cells 
and cleavage by a tumor-specific enzyme) has been characterized, the composite PAT 
structure has not yet been synthesized or analyzed.  Colocalization of both targeting 
elements on the surface of a single nanoparticle can be accomplished by combining 
elements described in this dissertation.  To facilitate construct synthesis, the linking 
chemistry (N-terminal primary amine) has been conserved between both the targeting and 
PA components.  Attachment of these constructs to the QD surface can occur by mixing 
the desired amounts of targeting ligand and PA construct and following the attachment 
protocol outlined in the current studies.  As both constructs utilize the same reaction 
chemistry and protocol, attachment to the QD surface is expected to occur with similar 
efficiency.  The difference in molecular masses of the two classes of molecular surface 
conjugates may modulate reaction kinetics and require adjustment to the vision of 
translating solution stoichiometry to relative surface concentrations.  Purification of the 
final PAT structure can be conducted by size exclusion using spin filtration as previously 
described. 
 
 
5.2.3 Assessment of PAT construct cleavage and binding properties 
 Validation of QD-PAT synthesis is not possible by the methodology utilized for 
either QD-PEG-NGR or QD-PA constructs, as these techniques are not capable of 
simultaneous measurement of both targeting and PA structures.  Thus, these proposed 
studies serve both as a validation of QD-PAT synthesis, as well as a functional validation 
of both the cleavage and binding properties of the construct. 
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In initial studies, the cleavage and binding properties of PAT QDs can be 
measured independently.  Construct susceptibility to exogenous MMP-7 can be assessed 
as described earlier for QD-PA constructs.  After exposure to MMP-7, gel electrophoresis 
can be performed to qualitatively assess construct cleavage.  QD constructs can then be 
purified by spin filtration and their emission profiles measured by fluorometry.  
Fluorometric measurements taken prior to and after cleavage are then compared to 
quantitatively determine the extent of construct cleavage from the QD surface. 
 Once the PA structures have been cleaved from the surface, the binding properties 
of the resulting targeted QDs can be determined.  A solution containing these pre-cleaved 
constructs can be added above a monolayer of target cells as previously described in Aim 
II.  Following incubation and washing, fluorescence microscopy can be used to visualize 
construct binding to the cell surface.  Flow cytometry can then be performed on the 
dissociated cell samples to quantitatively determine the extent of QD binding. 
This method effectively decouples the cleavage and binding processes, as each 
can be measured quickly and independently.  Furthermore, pilot studies reduce the 
complexity of the system by removing the intricate processes and variables associated 
with cellular experimentation.  Once the success of each process is verified in the PAT 
structure, additional cleavage and binding studies can be performed. 
 Once PAT construct cleavage and binding has been confirmed and validated in 
pilot studies, these properties can be assayed in in vitro cellular environments.  Construct 
cleavage can be assessed as described in Aim III.  Briefly, PAT QDs are added to cell 
monolayers in culture.  Following incubation, culture medium is sampled.  MALDI-TOF 
may potentially be used to determine the presence of cleavage products in the culture 
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medium samples.  QD particles remaining in solution can be purified by spin filtration 
and cleavage assessed by fluorometry and gel electrophoresis.   
 Cellular binding of the cleaved PAT QDs can be assessed as described for QD-
PEG-NGR particles in Aim II.  Culture media is aspirated and the cell monolayers are 
washed thoroughly with fresh PBS to remove any unbound QDs.  Adherent cells are 
removed from the surface via treatment with a nonenzymatic dissociation solution and 
analyzed by flow cytometry.  QD binding is assessed quantitatively by application of 
standard curves for conversion of measured fluorescence values. 
 
 
5.2.4 Possible limitations 
 As this anticipated work is a combination of Specific Aims II and III of this 
dissertation, all limitations described in those sections are applicable here.  In addition, 
the cleavage and binding characteristics of PAT QDs may differ significantly from those 
of QD-PEG-NGR and QD-PA constructs, and may be insufficient for effective NP 
targeting.  Once the cleavage and binding properties of these particles are determined, 
PAT QD functionality can be optimized to maximize both processes.  PEG length can be 
varied to modulate both enzyme access and binding characteristics, materially affecting 
the performance of the particle.  Furthermore, QD surface density and ratio of both PEG-
NGR and PA constructs can be varied to optimize performance of the final construct. 
 
 
5.3 Protection of Research Subjects 
No live animals were required for the completion of this work, and all animal-
derived tissue use has been minimized.  Animal-derived tissue was utilized in a fashion to 
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minimize the total number of animals necessary.  Primary and immortalized human cell 
lines were purchased directly from established vendors that comply with legal standards 
for collection and use of these cell lines. 
Appropriate training on general lab safety, standard chemical, biological and 
radiation safety, and animal techniques and procedures was performed for personnel 
involved in this study in compliance with institutional guidelines.   
 
5.4 Societal Implications 
Legal and ethical concerns of this work are minimal, as it extends prior work to 
target established therapeutics to a major source of worldwide morbidity and mortality.  
Successful development of the nanoparticulate constructs envisioned here has the 
potential for significant economic results, including the production of intellectual and 
physical property of substantial value to both the developing institution and any potential 
industrial partners. 
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